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1 Introduction and Objectives 
1.1 Introduction 
In 1980 the World Health Organisation (WHO) declared smallpox eradicated due to an 
effective, internationally coordinated mass vaccination campaign. In another success 
story, polio was defeated in all but some remaining geographical pockets and infectious 
diseases such as diphtheria or tetanus are not life-threatening anymore [1]. Vaccination 
in general can be regarded as one of the most cost-effective health-care interventions; 
diseases such as cancer, HIV and tuberculosis for which preventive or therapeutic 
vaccines are not available (yet) however lack such effective therapy [2]. The public’s 
overall positive perception of vaccination took a hit when in 1998 The Lancet published 
a paper linking the measles-mumps-rubella vaccine with autism even though the paper 
was later withdrawn because it was found to be erroneous and misleading [3]. 
Furthermore, it is very difficult to develop vaccines for pathogens with a high antigenic 
drift because their surface antigens change [4] and in case of the influenza virus this 
even leads to the need for a new vaccine every year because the surface antigens are 
used as antigens in the vaccine. In some years, e.g. the winter 2017/18, this vaccine does 
not match the actually circulating influenza isolates [5,6] and thus, the public’s 
vaccination willingness is yet lower. It can therefore be inferred that there is a need for 
the development of novel and broader effective vaccines conferring protection even 
against fast shifting antigens, which are simultaneously safe to use. 
Today, vaccines are mostly formulated as solutions or suspensions for injection. The 
antigen usually consists of live attenuated pathogens, whole inactivated organisms or 
inactivated bacterial toxins. Especially the attenuated pathogens are considered highly 
immunogenic while being minimally virulent. However, with those pathogens there is 
still a risk of regaining virulence [7]. Consequently, those vaccines carry the risk of severe 
adverse effects and even the break-out of the disease the vaccine was supposed to 
prevent. Having made this experience, safety is ranked very important in vaccine 
development nowadays and accordingly newly developed vaccines will probably not 
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contain live attenuated pathogens [4]. Inactivated organisms are safer but also less 
immunogenic in comparison to live attenuated pathogens. The lack in immunogenicity 
will be even more pronounced if only subunits instead of the whole organism are used 
as antigen. These could be a toxin or a capsular polysaccharide from encapsulated 
bacteria [4]. To overcome this lack in immunogenicity, adjuvants that enhance, 
modulate and/or prolong the resulting immune response are used [8]. Adjuvants 
furthermore allow the reduction of antigen load and antigen doses while stabilising the 
vaccine formulation during storage [9]. For this purpose, nowadays mostly alum is used 
but the implementation of new adjuvants, especially if utilising other routes of 
administration than injection, is sought after. Nanoparticles (NPs), for example, have 
been identified as potential antigen carriers that simultaneously exhibit adjuvant 
properties [10]. Other potential new adjuvants include chitosan, emulsions or pattern 
recognition ligands [11–13]. 
Alternative routes of administration (other than injection) are considered because the 
parenteral route is generally not known to induce a strong mucosal but merely systemic 
immunity. Mucosal immunisation with a particulate antigen which can be processed 
locally has been shown to induce both mucosal and systemic immunity [14], rendering it 
a favourable route of vaccine administration. This does not come as a surprise, since 
most pathogens enter the body via a mucosa. Nasal administration, being one 
opportunity for mucosal administration, bears the advantage of being independent of 
sterile equipment for administration and the nasal tissue is easily accessible as well as 
highly vascularised [15]. Challenges associated with this route of administration include 
achieving a sufficient dwell time of the formulation on the mucosa (to ensure uptake 
into and activation of antigen presenting cells, APCs) due to mucociliary clearance and 
the complex geometry of the nose with a narrow entrance and further narrow passages 
[16]. 
 
Introduction and Objectives 3
 
 
1.2 Objectives 
The aim of this work is to investigate NPs as potential antigen carriers for vaccine 
formulations. Chitosan will be used as particle forming polymer because it is widely 
discussed in literature as excipient in vaccines due to its adjuvant potential [10,17–19]. 
The understanding of the particle formation process between chitosan and a counterion 
by ionic gelation and influencing factors on that process as well as the optimisation of 
the loading of a model antigen in the NPs will be part of this work. 
To make the NPs applicable they will be incorporated into a microparticle matrix (Nano-
in-Microparticle, NiM), which is suitable for nasal administration, as schematically shown 
in Figure 1-1. 
 
Figure 1-1. Scheme of the proposed NiM formulation. 
The developed formulation will be investigated regarding its aerodynamic behaviour in 
terms of dispersibility from nasal powder device, nasal deposition and fine particle 
fraction (FPF). Upon deposition the microparticle matrix should dissolve and release the 
NPs. The in vitro uptake of those redispersed NPs into human dendritic cells (DCs) will 
be assessed to gain a first idea of the particles’ potential for vaccine delivery. 
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2 Theoretical Background 
2.1 Anatomy and Physiology of the Nose 
The nasal cavity has gained more and more interest in the academic community and in 
the pharmaceutical industry by offering a potential as an administration route not only 
for local but also for systemic drug delivery [20–22]. It is of particular interest for nose-
to-brain delivery (bypassing the blood-brain barrier) of substances such as fentanyl [23]. 
Due to the presence of many immune competent cells in the nasal tissue, it is 
furthermore a particularly interesting administration site for vaccines [15,24]. 
 
2.1.1 Anatomy of the Nose 
The nose can be divided into the outer and the inner nose. The latter is separated into 
two (usually dissimilar) halves by the nasal septum (septum nasi). Each half can be 
subdivided into the nasal vestibule (vestibulum nasi) and the nasal cavity (cavum nasi). 
At the transition between the nasal vestibule and cavity the nasal valve (limen nasi) is 
located, an important structure as it usually exhibits the narrowest diameter in the inner 
nose and thus has considerable impact on respiration and particle deposition. The air is 
accelerated here before slowing down and being swirled in the anterior nasal cavity 
which exhibits broader structures [25]. Each nasal cavity is confined dorsally by the 
posterior nasal aperture (choana) and both halves are merged in the nasopharynx [26]. 
Each nasal cavity has a volume of approximately 7.5 mL in an adult [21]. A schematic 
image of the nose, depicting details in the nasal cavity is shown in Figure 2-1. 
Each lateral nasal wall holds three bony turbinates (conchae nasales) which are covered 
by mucous membranes. They increase the specific surface area of the nasal cavity to 
approximately 130 cm² for both nasal cavities (150 cm² total surface area of the nose) in 
adults [27]. The turbinates simultaneously structure the nasal cavity in three passages 
(meatus nasi): the inferior nasal passage between the nasal floor and the inferior 
turbinate, the middle nasal passage between the inferior and the middle turbinate and 
the upper passage between the middle and superior turbinate. Above the latter the 
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olfactory region is located. Furthermore, the lateral walls of the nasal cavity are 
connected to the nasal sinuses (sinus paranasales) via narrow openings [26]. 
 
Figure 2-1. Sagittal section of the upper airways with details of the nasal cavity, adapted 
from [28]. Details on depicted tonsils are explained in section 2.2.1.1. 
The inner nose is covered by either respiratory or olfactory mucous membranes [25]. 
The olfactory mucosa can be found in the olfactory region and is characterised by the 
presence of Bowman's glands. Enzymes secreted by those glands serve olfaction. 
The other parts of the nose, including the nasal turbinates and sinuses, are covered by 
the respiratory mucosa which is highly vascularised [29]. It consists of a multi-layered 
ciliated epithelium and comprises mucous glands [30]. The epithelium is covered by 
secretions which form a double layer, as depicted in Figure 2-2. 
 
Figure 2-2. Secretions covering the nasal epithelium which can be divided in the periciliary 
fluid (7 - 10 µm) and the mucus layer (0.5 - 2 µm), adapted from [31]. 
The periciliary fluid, which is depicted in grey in the illustration, is of low viscosity while 
the mucus layer above exhibits a higher viscosity and non-Newtonian viscoelastic 
properties. It consists of 95 % water, 2 - 3 % glycoproteins, 1 % other proteins, 1 % salts 
and < 1 % lipids and is replaced approximately every 15 min [31]. Being a glycoprotein, 
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mucin is the principal polymeric component in the mucus and its quaternary structure is 
responsible for its gel-forming properties. It has a polyanionic character at neutral pH 
because of many sulphate and sialic residues [32]. The mucus and entrapped particles 
are moved to the nasopharynx due to ciliary action at a rate of (usually) 4 - 6 mm min-1. 
There can be variation due to diseases and in between individuals [21,31]. 
In contrast to the posterior parts of the nasal cavity, the anterior parts (including the 
front surfaces of the turbinates) are coated with non-ciliated epithelium. Thus, removal 
from those regions is slower [21]. 
 
2.1.2 Physiology of the Nose 
The nose is the preferred airway for respiration during sleep, rest and mild exercise. 
Nasal breathing is even obligatory in neonates [25,33]. Moreover, filtration and 
conditioning of the air as well as olfaction are functions of the nose [31]. The smell 
perception takes place in the olfactory region located in the superior part of the nasal 
cavity [26]. The inhaled air mostly flows through the middle nasal passage, exhaled air 
through the inferior nasal passage as well [30]. While the air is inhaled, it gets warmed 
(to 31 - 34 °C) and humidified by evaporation of nasal fluids. Furthermore, the air is 
cleared from airborne contaminants (or drug particles and droplets) which are 
entrapped in the nasal hairs and the mucus. The particle filtration efficiency from the air 
is dependent on the size and foremost due to inertial impaction. Particles above 10 µm 
are to be expected to deposit in the nose [21]. 
 
2.2 Vaccination 
The observation that one person usually does not suffer from the same disease more 
than once has already been made in ancient times. It led to the practice of inoculation 
of healthy persons with small amounts of infectious material obtained from persons 
infected with smallpox, with the aim of achieving immunity while lowering risks 
associated with the naturally occurring disease (mortality of 20 - 30 %) [34,35]. In China 
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this practise was already documented a thousand years before Edward Jenner started 
with the modern vaccination. In 1796, rather than inoculating with infectious material 
obtained from patients who were suffering from smallpox, he used material obtained 
from cowpox. He did this because he observed an immunity of milkmaids against 
smallpox after having suffered from cowpox, a harmless infection for humans. Hence, 
inoculation with cowpox led to a comparable immunity against smallpox while 
minimising risk of adverse effects [34]. Due to this tremendous success the word 
“vaccination” was derived from the latin word vacca for cow. 
In the late 19th century Paul Koch identified microorganisms as a cause of infectious 
diseases and Louis Pasteur developed the first attenuation method for pathogens [34]. 
Those pathogens were less infectious while maintaining their immunogenic properties 
leading to the development of vaccines against rabies and cholera [36]. In the following, 
killed pathogens were utilised for vaccines as antigens. In the 1920s even antigens only 
containing inactivated toxins, so called toxoids, from diphtheria and tetanus were 
adopted [34,37]. While decreasing the risk of severe adverse effects more and more by 
using smaller parts of the pathogen, the immunogenicity is lowered as well. Hence, 
adjuvants (derived from the latin word adjuvare for helping) were used with the aim to 
enhance and prolong the immune response [34]. More information on this topic will be 
provided in chapter 2.3.1. 
In vaccination adverse effects are an important topic because they are only sparsely 
tolerated. This is because vaccines are given to healthy persons in contrast to other 
medication, which is given to sick persons. Those patients bear greater adverse effects 
because the disease they suffer from is (usually) worse. A distinction can be drawn 
between adverse effects related to the vaccine, those associated with the vaccination 
procedure and those arising simultaneously with the vaccination by chance [38]. At 
present, most vaccines are administered intramuscularly. Hence, adverse effects are 
likely to occur due to the injection procedure (e.g. accidental needle sticks, use of 
contaminated needles) [7]. Figure 2-3 shows the potential impact of adverse events on 
the success of a vaccination campaign. 
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Figure 2-3. Potential stages in the evaluation of an immunisation programme linking the 
disease’s incidence, vaccine coverage and adverse events, adapted from [39]. 
In stage 1 (before a vaccine is available), the disease incidence is high. When the vaccine 
becomes available, the vaccine coverage increases and simultaneously the disease 
incidence decreases. With rising vaccine doses applied, the number of adverse events 
(vaccine-related, vaccination process-related and coincidental) increases (stage 2). After 
a while the threats of the disease become less visible due to low incidence, on the other 
hand the adverse events come to the fore resulting in loss of public confidence in the 
vaccine. Therefore, vaccine coverage falls again (stage 3) which concurrently raises the 
probability of new outbreaks of the disease. Triggered by such an outbreak, the trust in 
the vaccine increases again, vaccine coverage increases (stage 4) and eventually the 
disease is eradicated. It is only at this time that the vaccine application can be stopped 
(stage 5) [39]. This figure stresses not only the need for public awareness campaigns 
about the threats of infectious diseases but also shows the need for new vaccines 
and/or other administration routes, which are associated with less adverse events 
because the success of an immunisation programme relies on it. Nasal vaccines 
(formulated as liquid or dry powder) are not administered invasively and hence might 
be a promising alternative to the nowadays commonly used parenteral vaccines 
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because they bear not such a high risk of vaccination-related adverse events, as 
accidental needle sticks [28]. 
 
2.2.1 Immunological Principles 
The immune system can be divided into the innate and the adaptive immune system. 
Both systems are necessary to effectively defeat pathogens. While the innate immune 
system is activated within hours, the adaptive one takes days when it has not 
encountered the pathogen before. Once it has, it is the most effective part of the 
immune system [40]. Both systems consist of cellular and humoral (soluble) components 
[1]. Granulocytes, natural killer cells, macrophages and DCs are cells, which belong to 
the innate immune system. The latter two cell types are APCs that are able to activate 
T- and B-lymphocytes, which represent the cellular components of the adaptive 
immune system. For this reason, macrophages and, in particular, DCs form an important 
link between the innate and the adaptive immune system. The humoral components are 
the complement system and soluble antibodies (immunoglobulins, Ig) for the innate 
and the adaptive immune system, respectively. The complement system, consisting of 
many plasma proteins, provides the fastest response to a pathogen (within hours). It 
eventually results in the lysis of the pathogen [40]. Alternatively, the pathogen can be 
phagocytosed and eliminated by the cellular components of the innate immune system. 
Those cells recognise the pathogens due to so called pathogen-associated molecular 
patterns which are present on many pathogens but not on body’s own cells [1]. The 
APCs not only eliminate the antigen, but furthermore present it via major 
histocompatibility complex I (MHC-I) or MHC-II to T- and B-lymphocytes which is key to 
activate the adaptive immune system [40]. Whether an antigen is presented via MHC-I 
or MHC-II is dependent on its type. An endogenous antigen (e.g. virus in an infected 
cell) is degraded by the proteasome complex and presented via MHCI-I to CD8+ 
cytotoxic T-cells [41]. By contrast, antigens, which are phagocytosed, are degraded by a 
pH decrease and cytotoxic molecules and presented via MHC-II for recognition by cluster 
of differentiation 4+ (CD4+) T-cells. This stimulates the CD4+ T-cells to mature into 
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helper T-cells (TH) type 1 or 2. Those can be differentiated based on the secreted cytokines 
[1]. While TH1 cells favour the development of a cellular immune response, TH2 cells 
favour the development of a humoral immune response by activation of B-cells that 
develop into plasma cells releasing the humoral component of the adaptive immune 
system – antibodies. Depending on the activating cytokine, different isotypes of antibodies 
can be produced [1,42]. Those usually lead to the lysis of the infected cells. At the end of 
an infection, another type of T-cells (regulatory T-cells) supresses further T-cell responses. 
Both, T- and B-lymphocytes form memory cells, which can intervene much faster upon 
re-infection than it was possible during the primary infection. A balanced immune 
response (cellular and humoral) after vaccination is considered optimal nowadays [42]. 
 
2.2.1.1 Nose-Associated Lymphoid Tissue 
While injected antigens evoke systemic immune responses, antigens which are 
administered at a mucosa also evoke a local immune response via the mucosal immune 
system. This is part of the adaptive immune system and belongs to the secondary 
lymphoid organs [40]. The nose-associated lymphoid tissue (NALT) is the site of the 
mucosal immune system in the upper airways and located in the human pharynx, as 
shown in Figure 2-4. 
 
Figure 2-4. Pharyngeal lymphoid tissue of Waldeyer’s ring, taken from [43]. 
It was first described in 1984 by Waldeyer and named after him. The NALT consists of 
the adenoid (or nasopharyngeal tonsil), the paired tubal and paired palatine tonsils and 
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the lingual tonsil [43]. In children the NALT is potentially distributed throughout the 
nasal cavity, increasing the chance of a contact between the antigen and the lymphoid 
tissue and therefore improving the potential immune response in children after 
administration of an intranasal vaccine [28,31]. 
 
The NALT comprises all immunocompetent cells that are necessary to induce an 
immune response: DCs, macrophages, T- and B-lymphocytes and microfold cells (M-
cells) [44]. The M-cells are specialised epithelial cells which can take up particles up to a 
size of 10 µm [45] and deliver them by transcellular vesicular transport to underlying 
immune cells that can process them [24]. M-cells and DCs are however not only present 
in the confined structure of the NALT but are distributed throughout the respiratory 
mucosa [10,46]. Pathogens or particles that are deposited in the nasal cavity can either 
be taken up by cells in the respiratory mucosa after overcoming the mucus layer or in 
the adenoid where they are transported to by mucociliary clearance [10,15]. Different 
mechanisms for particle uptake are displayed in Figure 2-5. 
 
Figure 2-5. Routes of mucosal immune induction in nasal and airways epithelia by 
antigen loaded NPs, taken from [10]. 
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NPs can be taken up directly by DCs via transepithelial dendrites (A). Alternatively, NPs 
can passively permeate through epithelial junctions and then be taken up by underlying 
DCs (B). Another option is the transcellular transport through M-cells and delivery to 
immune cells that are present in the underlying pocket (C). Other possibilities include 
uptake of the NP via endocytosis in an epithelial cell, which can trigger the immune 
response by the release of cytokines, or presentation via MHC-I to T-lymphocytes. 
Particles with sizes ranging from a few hundred nanometres up to a few micrometres 
can be taken up by DCs [47]. Hamdy et al. described NPs as preferred over 
microparticles if targeting DCs because smaller particles are rather taken up by DCs 
while macrophages ingest larger particles [48]. Different preferred NP sizes are 
described in the literature, e.g. 20 - 80 nm [10] or 250 - 400 nm [49], depending on 
parameters such as the flexibility of the NP. Concluding from the abovementioned 
literature sources, this project aimed for particle sizes below 500 nm to enable preferred 
uptake into DCs. 
Activated DCs either stimulate a local immune response by presenting the antigen to 
neighbouring lymphocytes or migrate to lymph nodes (in the nose preferably to the 
posterior cervical lymph nodes) to stimulate an additional immune response. 
Depending on the lymph node in which the further processing takes place, different 
types of antibodies are produced by plasma cells. While the posterior cervical lymph 
nodes induce so called homing of immunocompetent cells and thus a local immune 
response (plasma cells release IgA) as well, the processing in the superior cervical lymph 
nodes and the spleen rather leads to a systemic immune response (plasma cells release 
IgG and IgM) [50]. Homing is the migration of lymphocytes back to their original tissues. 
Due to homing receptors, which bind tissue-specific chemokines, cytokines or adhesion 
molecules, lymphocytes find their original mucosa. Moreover, homing is directed by 
chemotaxis controlling the lymphocyte migration [40,51]. 
In addition, plasma cells releasing IgA can appear not only at the mucosal site of 
primary infection or immunisation, but also at distant mucosal sites. This feature is 
referred to as the “common mucosal immune system” [15,52]. The extent to which IgA is 
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expressed at those distant mucosal sites by plasma cells is dependent on the route of 
primary infection, e.g. infection or immunisation via the nose not only stimulates an 
immune response in the respiratory tract but also results in a strong genital-vaginal 
mucosal immune response [51]. Secretory IgA (sIgA) antibodies are usually found in a 
dimeric or multimeric form in mucosal secretions and are relatively resistant to 
enzymatic degradation. Those antibodies play a leading role in the neutralisation of 
pathogens prior to infection directly in the mucosa [24]. 
 
2.2.2 Immunisation Strategies 
Usually an immunisation is a preventive action, which can be divided into the active and 
the passive immunisation. Another field is the therapeutic immunisation. 
In case of an active immunisation a vaccine is administered to an antigen naïve 
individual. This induces an immune response building up over 10 - 14 days which leads 
to the development of memory T- and B-lymphocytes [34]. Usually this immunisation is 
repeated within a short period of time (two to four weeks) to boost the affinity of the 
secreted antibodies. This achieved immunity can last life-long [1,53]. Passive 
immunisation on the other hand does not provide a long-lasting but immediate 
immunity. It is performed in emergencies by administrating antibodies after an infection 
that one is not immune to, e.g. tetanus or snake venom [40]. In contrast, therapeutic 
vaccines are developed as future cures to pre-existing conditions such as cancer, 
chronic infections (HIV, hepatitis, tuberculosis) or Alzheimer’s disease, just to name a 
few [54–57]. 
 
2.2.3 Routes of Administration 
Vaccines can be delivered to humans via different administration routes. Nowadays, the 
most typically used is the intramuscular (or subcutaneous) injection [7]. This route 
however bears some disadvantages and thus other administration routes have been 
under research. Needle-free routes are the cutaneous and the mucosal immunisation, 
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i.e. nasal, oral, pulmonary or ocular immunisation [7]. Slütter et al. listed advantages and 
disadvantages of different administration routes as shown in Table 2-1 [58]. 
Table 2-1. Advantages and disadvantages of different vaccine administration routes, taken 
from [58]. 
Immunisation route Advantages Disadvantages 
Parenteral  Powerful systemic immune 
response 
 Accurate dosing 
 Invasive 
 Limited mucosal immune 
response 
Nasal  Non-invasive 
 Mucosal and systemic 
immune response 
 Easily accessible 
 Little degradation 
(compared to oral) 
 Mucociliary clearance 
 Inefficient uptake of soluble 
antigens 
Oral  Non-invasive 
 Mucosal and systemic 
immune response 
 Large surface area 
 Vaccine digestion in 
stomach and gut 
 Inefficient uptake of soluble 
antigens 
 Mucosal tolerance 
Pulmonary  Non-invasive 
 Mucosal and systemic 
immune response 
 Little degradation 
(compared to oral) 
 Delivery of antigen highly 
variable between persons 
 Clearance from lungs 
Dermal  Non or minimally invasive 
 Large, easily accessible 
application area 
 High density of immune 
cells in skin 
 Mucosal immune response 
possible 
 May require (minimally) 
invasive technology 
 Less established technology 
In addition to Table 2-1 it might be said that after parenteral vaccination no mucosal 
immunity instead of a limited one is to be expected because the antigen will most likely 
not be processed locally. The same is true if a soluble antigen is used in nasal 
vaccination. The problem with the soluble antigen will probably not be the uptake but 
rather the local processing, which is key in inducing a mucosal immune response. 
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Most pathogens enter the body via a mucosa, consequently this route is very promising 
for vaccination [28,59]. Especially the nasal vaccination has been of great interest 
because the nose is not only easily accessible but also highly vascularised and 
furthermore comprises the immune competent NALT. Moreover, immune responses 
can be induced at distant mucosal sites, as mentioned before in chapter 2.2.1.1. Another 
advantage is the potential of self-administration, enabling the easy immunisation of 
large population groups [60]. Mucosal vaccination is nonetheless very challenging as 
illustrated by the low number of registered mucosal vaccines. Most of them are for oral 
use (i.e. cholera, polio, rotavirus) and only Fluenz® (marketed as FluMist™ in the United 
States, USA, and in Canada), a vaccine against influenza, for nasal use. In this product, a 
live attenuated virus is used as antigen [61]. 
The challenges, mentioned in Table 2-1, have yet to be overcome. The requirements for 
the formulation are thus increased compared to injected vaccines. More light will be 
shed on this topic in the following chapter 2.3. 
 
2.3 Vaccine Formulations 
Registered vaccines can be divided into three categories as described earlier. Vaccines 
contain live attenuated pathogens, killed pathogens or subunits (toxoids or surface 
proteins). The immunogenicity is highest for the live attenuated pathogens, decreased 
in killed pathogens and even lower for subunit antigens. Hence, the need for adjuvants 
to enhance the immune reaction is greatest in subunit vaccines [62]. With decreasing 
immunogenicity, the safety of a vaccine increases. A live attenuated pathogen as 
antigen bears the highest risk of adverse effects because the pathogen might become 
virulent again and even evoke the disease it was supposed to protect against [4]. 
In addition to the antigen, vaccine formulations usually include stabilisers (to stabilise 
the antigen), inactivation substances (e.g. formalin to transform toxins to toxoids), 
residues from the manufacturing process (e.g. cellular components of hen’s eggs, 
antibiotics), preservatives (to prevent a contamination of the vaccine) and adjuvants 
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(enhancement of the immune reaction) [63]. The latter will be further discussed in the 
following chapter 2.3.1 because they are particularly important in subunit vaccines that 
are administered intranasally. 
 
2.3.1 Adjuvants 
The use of adjuvants has a long history. Aluminium hydroxide and phosphate, 
commonly referred to as alum, have been used for almost 90 years to enhance the 
immune response to a vaccine [64]. Alum is the most widely used and most frequently 
studied adjuvant. Its effect probably relies on a depot effect (slow release of the 
adsorbed antigen). Moreover, Alum leads in vivo to the secretion of high levels of 
antigen-specific antibodies, hence to a preferential humoral immune response. If a 
cellular immune response however is needed (e.g. intracellular pathogen), alum will not 
be suitable [64,65]. 
A mere 20 years ago another adjuvant, MF59 (microfluidised emulsion 59), was first 
used in an influenza vaccine (Fluad®, Novartis, Switzerland) [64,66] even though the 
use of emulsions as adjuvant has been studied since 1930 (Freund’s Complete 
Adjuvant). MF59 is an oil-in-water emulsion that mostly consists of squalene and is 
stabilised by polysorbate 80 and sorbitane trioleate 85 [64]. Many other adjuvants are 
discussed in the literature not only regarding their immune enhancing capacity but also 
its pathway, which might direct the immune response towards a humoral and/or a 
cellular mediated one [67]. Different postulated mechanisms include depot formation, 
recruitment of immune cells, activation of the inflammasome, enhancement of antigen 
presentation by MHC molecules or immunomodulation [9]. 
Moreover, it must be differentiated between adjuvants being effective after parenteral 
injection and those after mucosal administration. Newsted et al. state that in 2015 none 
of the licensed adjuvants revealed a strong enhancement of the immune response after 
mucosal administration [68]. They furthermore report that mucosal adjuvants can be 
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separated into two groups: immunostimulators and vehicle delivery systems. Examples 
for those two groups are given in Table 2-2. 
Table 2-2. Types of mucosal adjuvants, taken from [68]. 
Immunostimulatory adjuvants Vehicle delivery systems (Nanoparticles) 
 Escerichia coli heat labile enterotoxin 
 Cholera toxin 
 Pattern recognition ligands 
 Cytokines 
 Mast cell activators 
 Virus-like particles 
 Liposomes 
 Nanogels/-emulsions 
While immunostimulators directly activate innate immunity, delivery systems protect 
antigens from the environment and target M-cells [68]. Some adjuvants exhibit 
immunostimulatory properties and are delivery system at the same time, such as 
chitosan and its derivatives. Chitosan is not only a potent immunostimulant but also a 
relatively safe penetration enhancer by translocation of tight junctions between cells 
[69,70] making it a very promising adjuvant. 
 
2.3.2 Special Requirements for a Nasal Nanovaccine 
A nasal nanovaccine must deposit safely in the nose and be taken up into immune 
competent cells to induce an immune response. Excipients prolonging the dwell time on 
the nasal mucosa, easing the uptake and enhancing the immune response would thus 
be favourable [58]. The nanoparticles must be formulated in a way that ensures their 
deposition in the nose. This could either be done by the formulation as a liquid 
producing large enough droplets or as a dry powder in a suitable size range of above 
10 µm (confer chapter 2.1.2). The use of a dry powder instead of a liquid as nasal vaccine 
alleviates storage and distribution requirements. Potentially not even refrigeration is 
necessary making a dry powder a favourable formulation, e.g. for mass vaccination 
campaigns in developing countries [31]. 
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2.4 Nanoparticles 
NPs were chosen as antigen carrier in this project. Therefore, this section gives a short 
overview of this topic. 
The field of pharmaceutical nanoscience, which has grown considerably over the last 
40 years, consists of many technologies, e.g. liposomes, nano-emulsions, polymeric 
NPs, carbon nanotubes or drug nanocrystals. Those are used for different applications 
in the field of cancer therapy, gene therapeutics, tissue engineering or vaccination [71]. 
Many applications exist for nanoscience, so many definitions exist for the definition of 
nano-objects. The FDA published a “guidance for industry” in 2014 that defines nano-
objects as materials in the nanoscale range (with at least one dimension in the size 
range of approximately 1 nm to 100 nm) or materials/end products outside the 
nanoscale range up to 1 000 nm, provided they can exhibit different chemical or 
physical properties, or biological effects compared to larger-scale counterparts [72]. 
Polymeric NPs are usually produced by bottom-up techniques (in contrast to top-down 
techniques, e.g. milling). Bottom-up techniques start with atoms or molecules, which are 
built up to form NPs by, e.g. solvent evaporation or ionic gelation. The last technique is 
limited to charged polymers that react with a contrarily charged molecule resulting in 
precipitation. Depending on the chosen experimental setup, they can be in the nano-
range. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Chitosan 
In this project, chitosan was used as particle forming polymer. It is derived from chitin, a 
natural polysaccharide which is produced in a variety of living organisms such as funghi, 
crab and shrimp. Chitosan is obtained via partial deacetylation under strong alkaline 
conditions. The substance is a random copolymer of β-1,4-N-acetyl-D-glucosamine and 
β-1,4-D-glucosamine [73], as shown in Figure 3-1. Chitosan is characterised by its 
degree of deacetylation (DDA) giving the ratio between the acetylated and the 
deacetylated glucosamine units. 
 
Figure 3-1. Chemical structure of chitosan depicting acetylated (A) and deacetylated (B) 
glucosamine units. 
In addition to the DDA, the molecular weight characterises a chitosan quality. In the 
used chitosan products, it is indirectly described by the viscosity of a 1 % solution in 1 % 
acetic acid (HAc) at 20 °C. Accordingly, the viscosity is used as marker for molecular 
weight within this project. If the molecular weight increases, viscosity increases as well. 
DDA and molecular weight are only given as average values but because of chitosan’s 
natural origin a statistical distribution is underlying these characteristics. 
Chitosan has raised quite some interest as excipient in medicinal products. It is soluble 
in acids because of its free amino groups, resulting in positive charges. This cationic 
character gives the opportunity to utilise it as excipient to promote mucoadhesive 
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properties by binding with negative sialic residues of the mucus (confer chapter 2.1.1), to 
control drug release by gel formation or to enhance permeation by transiently opening 
tight junctions [74–76]. Chitosan is biocompatible, biodegradable, non-toxic and non-
immunogenic [75]. As mentioned earlier (chapter 2.3.1) chitosan exhibits adjuvant 
properties if used for mucosal vaccination. All these characteristics make chitosan a very 
promising particle forming polymer in the field of vaccination [19]. 
Table 3-1 summarises the properties of the chitosan qualities used, given as mean 
values (confer above). In general, qualities from Heppe Medical Chitosan (Germany) 
exhibit narrower distributions for molecular weight compared to other suppliers. For 
every experiment, the used quality is denoted. 
Table 3-1. Details of chitosan qualities (all obtained from Heppe Medical Chitosan, 
Germany) as stated by the supplier. For the quality Chitoscience 90/10 three batches were 
used, indicated by a-c. 
Chitosan quality DDA, % Viscosity of 1 % solution in 1 % HAc at 20 °C, mPa s 
Chitoscience 70/20 71.5 23 
Chitoscience 70/50 69.1 45 
Chitoscience 75/10 75.7 11 
Chitoscience 80/20 78.7 23 
Chitoscience 80/50 79.8 37 
Chitoscience 85/10 84.4 10 
Chitoscience 90/10a 90.1 15 
Chitoscience 90/10b 88.1 8 
Chitoscience 90/10c 87.7 14 
Chitoscience 90/20 90.2 18 
Chitoscience 90/200 88.5 220 
Chitoscience 90/50 90.2 49 
Chitoscience 95/10 96.1 15 
Chitoceuticals 95/20 96.4 23 
 
3.1.2 Sodium Carboxymethylcellulose 
As second particle forming polymer sodium carboxymethylcellulose (CMC), a low 
viscosity carboxymethylcellulose sodium salt (Sigma-Aldrich, USA) was used. It is a 
semisynthetic, linear polysaccharide, shown in Figure 3-2. Its average degree of 
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substitution is 0.65 - 0.90 according to the product’s specification. CMC qualities with a 
degree of substitution above 0.45 are soluble in water. In contrast to chitosan, CMC is 
negatively charged if dissolved in aqueous media between pH 2 and 10 [77]. 
 
Figure 3-2. Chemical structure of CMC, R can be H or COONa. 
In the pharmaceutical industry it is usually used as a thickening agent in gel 
formulations and oral suspensions, as a stabiliser for emulsions or as a binder for wet 
granulation [78]. In this project, given by its negative charge, it is used as a counterion 
for chitosan. 
 
3.1.3 Sodium Deoxycholate 
Sodium deoxycholate (DOC), obtained from Carl Roth, Germany, was used for some 
experiments as an alternative particle forming excipient, replacing CMC. With a 
molecular weight of 414.64 g mol-1, it is a rather small molecule compared to the other 
particle forming excipients. The supplier states that solubility in water is 330 g L-1 at 
15 °C. The chemical structure is depicted in Figure 3-3. 
 
Figure 3-3. Chemical structure of DOC. 
22 Materials and Methods 
 
 
Naturally, this component can be found in the bile. It is the sodium salt of the secondary 
bile acid deoxycholic acid which is derived via dehydroxylation from primary bile acids 
by bacterial enzymes [26]. Salts from bile acids show permeation enhancing effects by 
temporary disruption of tight junctions. That is why they are among other things used 
as excipients in nasal drug delivery. Because of this permeation enhancing effect, which 
might facilitate particle uptake, it is of interest in the field of vaccination. Moreover, it 
increases the humoral immune response and it does not show toxic effects in 
concentrations of 0.5 - 1 % [79]. 
 
3.1.4 Ovalbumin 
Ovalbumin (OVA) is the most abundant protein in egg white. It consists of 386 amino 
acids [80]. The glycoprotein’s function has not yet been elucidated even though OVA 
was one of the first purified proteins [81]. During storage the native ovalbumin converts 
into a more stable form (S-Ovalbumin), showing an elevated degradation temperature 
of 86 °C compared to 78 °C for the native form. A lyophilised powder of > 98 % purity 
(Sigma-Aldrich, USA) with a molecular weight of 44.3 kDa and an isoelectric point (IEP) 
at pH 4.5 was used. 
OVA is a well-established model protein for immunological studies in murine 
DCs [82,83]. The amino acids 257-264 (SIINFEKL) could be identified as the epitope 
inducing a cytotoxic T-cell response [84–86]. 
 
3.1.5 Mannitol 
D-Mannitol (Figure 3-4) is a crystalline powder with a solubility of approximately 
213 g L-1 at 20 °C, a melting point of 165 - 170 °C and a molecular weight of 
182.18 g mol-1 [87]. Due to a very low glass transition temperature of -5 °C [88] mannitol 
is crystalline even after a fast drying process as spray drying. Being a non-reducing 
sugar alcohol makes it an attractive matrix material for microparticles. Reducing sugars 
in contrast could interact with free amino groups, which are present in every protein, in 
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a maillard reaction, potentially inactivating the protein. In the pharmaceutical industry, 
mannitol is used as an excipient in tablet or capsule formulations. Furthermore, it can be 
used as carrier in dry powder inhalation [88]. Bronchitol®, a product with mannitol as 
active pharmaceutical ingredient, has been on the market for the treatment of cystic 
fibrosis since 2012 [89]. In this work, Pearlitol® 300DC (Roquette, France) was used. 
 
Figure 3-4. Chemical structure of D-Mannitol. 
 
3.1.6 Fluorescein Isothiocyanate Isomer I 
NPs were rendered visible for cell studies by the addition of fluorescein isothiocyanate 
isomer I (FITC) to chitosan. FITC, the derivative of fluorescein with an isothiocyanate 
group, is reactive towards amino groups which are present in many biomolecules [90]. It 
is a rather small molecule with a molecular weight of 389.4 g mol-1 [91], as shown in 
Figure 3-5. The used FITC had purity above 90 %, suitable for protein labelling (Sigma-
Aldrich, USA). 
 
Figure 3-5. Chemical structure of FITC. 
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3.1.7 UDS Powder 
The UDS powder (Aptar Pharma, France) was used for aerosolisation of the dry powder 
formulation. The UDS stands for unit dose system in this context. The UDS powder is a 
single dose and use device for nasal application. It is suitable for vaccination because 
such a formulation would only require a once at a time application. Figure 3-6 depicts 
the UDS powder with its inner construction. 
 
Figure 3-6. Image (left) and schematic figure of the UDS powder with inner construction 
(right), reprinted with permission from Aptar Pharma. Letters A to G indicate the 
functional components of the device. 
Approximately 20 mg powder (C), exactly weighed, was filled manually into a cartridge 
(B) which is closed on one side with a plastic thorn (D) and on the other with a plastic 
ball (A). The cartridge was placed in the releasing tube prior to the final assembly using 
special assembly tools. The device was actuated by pressing the lower part (G) up. 
Doing so, the air (E) in the entire system was compressed, the bar (F) pushed up the 
thorn which then itself pushed up the ball. Consequently, the dose was released by 
expansion of the compressed air through the releasing tube. 
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3.2 Preparative Methods 
3.2.1 Ionic Gelation 
The particle formation method of NP consisting of chitosan and CMC was adapted from 
[92]. NPs were prepared by ionic gelation enabled by the contrarily charged particle 
forming polymers – chitosan positively and CMC or DOC negatively charged. The 
charges were obtained by dissolving the polymers in diluted HAc (chitosan) and in 
ultrapure water (CMC and DOC), respectively. They were left over night at room 
temperature to allow complete hydration. A standard concentration of 0.1 wt% for all 
polymers was used. 
For experimental and cost-containment reasons, the batch size was typically set to 
10 mL. The chitosan solution was filled into a small vessel and stirred by a magnetic 
stirrer (IKAMAG® RET, IKA®-Werke, Germany) at 700 rpm. The counterion solution 
(CMC or DOC) was added slowly by an automatic pipette (lowest dosing speed, 
Eppendorf Research® Pro, Eppendorf, Germany) to the chitosan solution. Directly after 
mixing the two solutions NPs formed resulting in a turbid suspension which was 
refrigerated for at least 30 min prior to further experiments. 
If OVA was added as model antigen, the protein was dissolved in a concentration of 
0.1 wt% in the chitosan solution shortly before NP production. 
 
3.2.2 Processing of Nanoparticles 
The particle formation by ionic gelation was not quantitative, meaning not all of the 
starting substances formed particles. Free chitosan, counterion (CMC or DOC) and (if 
added) OVA were present. If they were left in the solution, they would potentially affect 
the resulting NiM. Hence, prior to further processing, the nanosuspension was washed 
via centrifugation to eliminate any free components in the supernatant as follows: 
Suspensions were separated by centrifugation according to size and density. The 
separation efficiency is influenced by the velocity and the radius of the centrifuge rotor. 
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Depending on the volume of the suspension that needs to be washed, different 
centrifugation schemes were utilised because the distance to the bottom of the tube 
(and thus the time for sedimentation) varied. All runs were performed at 15 °C because 
it was found that this reduced temperature helps to avoid that particles stick to each 
other and/or to the wall of the tube. Washing of 10 mL nanosuspension (in a 50 mL 
centrifuge tube) was done in one step for 60 min at 3 500 rcf. For a larger volume of 
50 mL the suspension was filled in a 50 mL centrifuge tube (largest volume possible 
using the Eppendorf 5430R centrifuge, Eppendorf, Germany) and centrifuged in 
multiple steps (each 5, 10, 15, 30 or 60 min) at velocities of 1 878 - 7 197 rcf, as adapted 
from [92]. 
After each centrifugation step the supernatant was discarded into another centrifuge 
tube and centrifuged again. The centrifuge tube with the pellet was put on a shaker 
(Schüttelapparatur Typ B1, Edmund Bühler, Germany) to gently redisperse the NPs in 
the remaining drop of supernatant. At the end, all redispersed NP pellets were united 
and refilled to the desired volume with diluted HAc. 
 
3.2.3 Fluorescence Labelling with Fluorescein Isothiocyanate Isomer I 
The covalent binding of a fluorescent dye to chitosan has one benefit over an 
encapsulated fluorophore: The dye cannot be separated from the particle in cell 
experiments allowing reliable conclusions. The method to label chitosan with FITC was 
adapted from Colonna et al. [93]. After dissolving 100 mg chitosan in 10 mL 1 % HAc 
(giving a concentration of 10 mg mL-1), 10 mL methanol was added to the mixture. 
Subsequently, 5 mL of a FITC (2 mg mL-1) in methanol solution was added resulting in a 
ratio of chitosan to FITC of 10:1 and left to react for 3 h (constant stirring in the dark at 
room temperature). The binding takes places between the free amino groups of 
chitosan and the isothiocyanate groups of FITC, as shown in Figure 3-7. 
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Figure 3-7. Reaction mechanism between FITC and chitosan. 
After 3 h, the labelled polymer was precipitated with 1 M NaOH (above pH 10). The 
precipitated polymer was washed by centrifugation with methanol/water (75:25) to 
remove free FITC molecules. Centrifugation for 5 min at 7 197 rcf and 25 °C was 
repeated until no more colouring had been detected in the supernatant. The washed 
FITC-chitosan was dissolved in 1 % HAc and dialysed in the dark (room temperature) 
against water for 3 d to remove any remaining FITC. For this, a dialysis tube with a 
molecular weight cut off of 3.5 - 5 kDa (Spectra/Por® Float-A-Lyzer® G2, Spectrum, 
Netherlands) was used. Finally, to allow storage, the FITC-chitosan was freeze-dried 
(ALPHA 1-4 with LDC-1M, Martin Christ Gefriertrocknungsanlagen, Germany). When the 
FITC-chitosan was used for particle preparation, the initial weight was increased by 5 % 
to account for the added FITC. 
 
3.2.4 Spray Drying 
Microparticles were formed via spray drying. This technique is suitable, if large amounts 
of solvent must be dried. It is widely used in the food industry, for example to spray dry 
milk [94], as well as in the pharmaceutical industry, where microparticles are produced 
for numerous purposes. Spray dried powders are used in dry powder inhalation, as 
excipients in tablets or for transdermal dosage forms [94,95]. They usually consist of 
hollow spheres, however, depending on substance characteristics many different 
morphologies, e.g. indented particles, can prevail [95]. Spray drying is a very fast drying 
method. The fluid is atomised in small droplets which are mixed with a drying gas, 
usually air [96]. The smaller the droplets, the faster the drying because of increased 
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surface and increased vapour pressure due to a stronger curvature, leading to a lower 
boiling point allowing faster drying [94]. 
Figure 3-8 depicts the Mini Spray Dryer B-290 (Büchi Labortechnik, Switzerland) used in 
this study. The spray drying process can be separated into three process steps: 
(1) atomisation, (2) drying and (3) separation. 
 
Figure 3-8. Schematic image of Mini Spray Dryer B-290 from Büchi Labortechnik, 
reprinted with permission from Büchi. 
The Mini Spray dryer B-290 works with co-current flow: drying gas is led in feed 
direction. (1) The feed was atomised by either a two-fluid or an ultrasonic nozzle, shown 
in Figure 3-9. 
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Figure 3-9. Schematic images of two-fluid (left) and ultrasonic nozzle (right) that were 
utilised in combination with the Mini Spray Dryer B-290 
The two-fluid nozzle consists of two telescoped concentric pipes where the feed is 
delivered through the inner and the spray gas through the outer pipe. These two 
components collide outside the nozzle which reduces sticking tendencies. The droplet 
size is controlled by the diameter of the inner concentric pipe, by the feed rate and the 
spray gas flow and by characteristics of the liquid, such as viscosity and concentration. 
The ultrasonic nozzle generates droplets by high frequent vibration at the atomising 
surface [94,97]. Ceramic piezoelectric transducers convert high frequency (60 kHz) 
electrical energy from an external power generator into mechanical energy (vibration) at 
the atomising surface, breaking up the liquid feed into single droplets. The power 
output at the nozzle can be varied between 1 - 15 W to match the feed and the feed 
rate in particular. The mist is slower than that coming from a two-fluid nozzle. Droplet 
size generated by this nozzle is governed by the power on the atomising surface, the 
feed rate and by liquid characteristics. If water is dispersed, the mean volumetric 
diameter typically is 50 µm, the underlying distribution follows a logarithmic normal 
distribution [97]. 
(2) The second step is drying; this step is mostly dependent on the inlet temperature 
and the flow rate of the drying gas. This step takes less than a second. For that reason 
spray drying is a very mild drying technique as the product does not need to withstand 
high temperatures for a long time. The maximal temperature the product is exposed to 
in the co-current procedure is the outlet temperature measured at the transition 
30 Materials and Methods 
 
 
between drying chamber and cyclone. The product does not need to endure the inlet 
temperature because of the evaporation cold which shields it. 
(3) The cyclone separates the dried powder particles from the air stream based on 
inertial forces. Particles that cannot be entrapped in the cyclone are separated from the 
airstream via a filter (those particles cannot be utilised; the filter only has the purpose of 
cleaning the air stream). 
Only aqueous dispersions were spray dried in this work, hence the B-290 was operated 
in the open cycle mode (air was used for operation of the spray dryer, in the closed 
mode an inert gas would be used enabling spray drying of explosive liquids, e.g. 
ethanol). The standard spray drying parameters are summarised in Table 3-2. 
Table 3-2. Standard spray drying parameters for two-fluid and ultrasonic nozzle. 
Nozzle type Two-fluid nozzle Ultrasonic nozzle 
Volume flow 35 m³ h-1 20 m³ h-1 
Spray gas flow 473 L h-1 Only needed for cooling of the nozzle 
Inlet temperature 80 °C 110 °C 
Outlet temperature < 40 °C < 40 °C 
Feed rate Adjusted to reach desired outlet temperature (10 - 15 %) 
Nozzle diameter 1.5 mm - 
Power output at nozzle - 1 W 
 
3.3 Design of Experiments 
In order to maximise what can be learned from conducted experiments an experimental 
design was used. By varying several factors simultaneously, the number of required 
experiments for a given problem can be kept relatively small. The influencing factors 
can be identified by applying mathematical models. They can then be used to optimise 
or even to predict the results of future experiments. 
In this thesis a central composite centre faced design was chosen to identify significant 
factors in spray drying utilising the ultrasonic nozzle. The design contained three factors 
at three levels including five centre points. The design of experiments (DoE) was 
generated using Modde Software (Version 10.1.1, Umetrics, Sweden) and resulted in 19 
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experiments. For model fitting only significant factors were considered while all others 
were excluded. This was performed individually for each response. 
The model can be described by four factors, namely R2 (model fit), Q2 (estimation of 
future prediction precision), model validity (a test of diverse model problems) and 
reproducibility (variation between replicates) [98]. 
 
3.4 Analytical Methods 
3.4.1 Determination of Molecular Weight 
One of two main characteristics of chitosan’s quality is its molecular weight. To gain 
more information about the molecular weight distribution size exclusion 
chromatography (SEC) experiments were performed. 
 
3.4.1.1 Size Exclusion Chromatography 
SEC is a liquid chromatographic separation method. In contrast to e.g. HPLC it does not 
separate substances according to their chemical reactivity but only by their molecular 
weight. Higher molecular weight substances are eluted earlier in comparison to those of 
lower molecular weight because they are less entrapped in the porous column material. 
Any interaction between the sample and the column material must be avoided if the 
aim is determining molecular weight or, more precisely, the hydrodynamic volume. The 
hydrodynamic volume can be derived from a calibration with linear polymer standards 
(e.g. pullulan) by means of the retention time. The hydrodynamic volume corresponds 
well with the molecular weight in case of a linear molecule. The estimated molecular 
weight of a branched polymer or one that interacts with the column material is likely to 
be underestimated when using this method (hydrodynamic volume smaller than 
molecular weight). The opposite case (hydrodynamic volume larger than molecular 
weight) might occur if a molecule generates a strong hydration shell resulting in a 
32 Materials and Methods 
 
 
shorter column retention time. If utilising a MALS detector the molar mass can be 
determined directly because the scattered light corresponds to the molecular weight. 
Experiments were performed with a PL-GPC 50 Plus (Polymer Laboratories, USA). The 
system contains an integrated degasser and a differential refractive index detector 
(Polymer Laboratories, Varian Inc., USA). Additionally, a MALS detector (Mini DAWN 
Tristar, Wyatt) was utilised for the determination of molar mass, assuming a refractive 
index increment of 0.185 mL g-1 for chitosan (taken from [99]). For the separation by 
size, a PL aquagel OH Guard 8 μm precolumn followed by a PL aquagel OH 40 8 μm 
column and one PL aquagel OH 30 8 μm column (all Agilent Technologies, USA) in 
series were used. Samples (3 mg mL-1 dissolved in 1 % HAc) were eluted with a mixture 
of 0.25 M NaNO3 und 0.01 M NaH2PO4 in water (pH 2.3) at a flow rate of 1.0 mg mL-1 
and the column temperature was kept at 35 °C. Pullulan calibration was used to 
determine the hydrodynamic volume of the samples. Those values were compared to 
molecular weight obtained from MALS results. 
 
3.4.2 Determination of Degree of Deacetylation 
In addition to the molecular weight, the DDA is a crucial characteristic of chitosan. It was 
determined for selected chitosan qualities to gain a better understanding of the particle 
formation process. 
 
3.4.2.1 1H-Nuclear Magnetic Resonance Spectroscopy 
Nuclear Magnetic Resonance Spectroscopy (NMR) relies on the absorption of nuclear 
magnetic resonance in a high frequency range of 60 - 600 MHz enabling the 
determination of the chemical structure. The phenomenon can be observed for a few 
atoms, such as 1H. 1H nuclei can exhibit different spin conditions (+½, -½) 
corresponding to different energy levels. If an external magnetic field is applied the 
protons align and take spin conditions at different energy levels. By application of 
external energy (radio radiation), the nuclei on the lower energy level (number of nuclei 
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on this level slightly higher than nuclei on the higher energy level if no energy is 
applied) will absorb energy and will be lifted to the higher energy level. NMR detects 
this absorption and plots it against the magnetic field strength. Depending on the 
environment (solvent, nearby atoms) of a 1H nucleus different signals (chemical shift) 
can be detected because the applied magnetic field is partially blocked. Those shifts are 
measured against a standard (usually deuterated sodium trimethylsilyl propionate, TSP) 
and are given in ppm [100]. All samples must be dissolved in deuterated solvents 
because protons present could lead to interferences. 
1H-NMR was utilised in this project to assess the DDA of chitosan. Experiments were 
performed by modifying the method of Lavertu et al. [101] to determine chitosan’s DDA. 
Samples were dissolved in 2 % CD3COOD (Carl Roth, Germany) to a concentration of 
5 mg mL-1. Measurements were performed with a BRUKER Avance III 300 MHz 
spectrometer (Bruker Corporation, USA) at 80 °C.  
Chemical shifts of samples are related to the external standard TSP and given as ppm 
downfield from TSP. The DDA was determined using Equation (3-1), taken from [101]. 
ܦܦܣ ൌ ܪ െଵ ܦ
ܪ െଵ ܦ ൅ ܪ െ ܣܿ3
ൈ 100 % (3-1)
The variables used (H‐1D and H‐Ac from the deacetylated and acetylated glucosamine 
units, respectively) are depicted in Figure 3-10. 
 
Figure 3-10. Positions of protons in chitosan monomers used for determination of DDA, 
adapted from [101].  
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3.4.3 Particle Size Determination 
Particles cannot be described by only providing their diameter without specifying the 
method applied for determination. Most particle size measurement methods simplify 
particles to spheres while making different further assumptions (for example, about 
density). Hence, diameters measured are dependent on the technique and known input 
parameters. Particles can be equivalent to a sphere with the same weight, volume, 
length or aerodynamic behaviour. 
Depending on particle size, different sizing techniques have been utilised for 
determination in this study. NPs were characterised by dynamic light scattering (DLS), 
giving an intensity-based particle diameter (z-average). Microparticles were measured 
with laser light diffraction resulting in a volume-based particle diameter. 
 
3.4.3.1 Dynamic Light Scattering 
Particles in the nanometre range usually do not undergo sedimentation but only 
Brownian motion. This random movement can be measured via dynamic light 
scattering, also known as photon correlation spectroscopy. Particles are illuminated with 
a laser and intensity fluctuations of the scattered light are subsequently measured [102]. 
The Stokes-Einstein-equation (Equation (3-2), taken from [103]) defines the relationship 
between Brownian motion and particle size. Dh stands for the hydrodynamic diameter, 
Dt for the translational diffusion coefficient, kB for the Boltzmann’s constant, T for 
temperature and η for dynamic viscosity, respectively. 
ܦ௛ ൌ ݇஻ ൈ ܶ3ߨ ൈ ߟ ൈ ܦ௧ 
(3-2)
This formula implies that small particles or particles in an environment with low viscosity 
move faster than large particles or particles in an environment with high viscosity. 
Hence, the knowledge of a sample’s viscosity at a given temperature is crucial for size 
determination. Particle size determined by DLS is usually given as z-average which is the 
normalised intensity weighted mean hydrodynamic size of measured particles. It is 
Materials and Methods 35
 
 
derived from cumulants analysis of the measured correlation curve coming from a 
single particle size and a single exponential fit is applied to the autocorrelation function 
giving Dt. The deviation of the correlation function from this autocorrelation function is 
used for determination of the polydispersity index (PDI) [104]. It can vary between 
0 and 1, 0 standing for a single particle size and 1 for widely distributed particle sizes. 
From the correlation function the intensity-based distribution can be calculated. 
Viscosity and corresponding temperature were determined with the SV-10 Vibro-
Viscometer (A&D Company, Japan) and the values utilised for subsequent DLS 
measurements. For those, the Zetasizer ZS Nano (Malvern Instruments, United 
Kingdom, UK) was used. Nanosuspensions were filled undiluted into disposable 
polystyrene cuvettes, placed in the Zetasizer and equilibrated for 2 min. The 
measurement consisted of three consecutive runs without a delay in between. Each run 
consisted of approximately 10 - 15 single measurements (exact number was determined 
automatically by the software). The laser emits light with a wavelength of 633 nm, the 
scattered light is detected at an angle of 173° (backscatter detection). This comprises 
advantages over a detection at 90°, for example, the option to measure higher 
concentration and the reduction of multiple light scattering (scattered light from one 
particle is subsequently scattered by another particle) [102]. Depending on the turbidity 
of the sample, the laser is more or less attenuated to avoid detector overload which is 
adapted by the Zetasizer automatically. 
 
3.4.3.2 Laser Diffraction 
Laser diffraction is a widely used technique as it allows evaluation of particle size in a 
very broad size range from 0.1 µm to several millimetres. The sample is exposed to laser 
light and based upon the angle and intensity of diffracted light the particle size 
(volume-based equivalent diameter) is determined based upon the Fraunhofer or the 
Mie theory. The Fraunhofer theory is especially advantageous because no additional 
optical parameters (e.g. refraction index) are needed for the analysis. The inflected light 
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is detected in an almost forward angle. Particle size is negatively correlated with 
diffraction angle [105]. Other phenomena such as absorption or reflection of light are 
not taken into account (in contrast to data evaluation according to the Mie theory). 
For experiments within this work the laser diffraction sensor HELOS® (Sympatec, 
Germany) was used in combination with the Windox® 5 software (Sympatec, Germany) 
applying the Fraunhofer enhanced equation for data evaluation. Particles above 1 µm 
can be analysed using this equation. The helium neon laser emits light at a wavelength 
of 632 nm. Depending on the particle size different lenses, R2-R5, with measuring 
ranges from 0.25 - 87.5 µm to 0.5 - 875 µm, respectively, were used. Measurements 
were performed in triplicate. Two different dispersion modules were applied, the 
RODOS® dry dispersion module for size determination of powders and the SPRAYER® 
module (both Sympatec, Germany) for size determination of powders emitted from 
UDS powder device. 
Using the RODOS® module the samples, which were fed manually, were dispersed via 
pressurised air. Particles below 10 µm were measured with a pressure of 3 bar while 
larger particles were measured with a dispersion pressure of 0.5 bar to prevent particle 
breakage while still ensuring efficient dispersion (determined experimentally). 
Measurements started at an optical concentration above 0.5 %. 
To assess the dispersing power of the UDS powder, the SPRAYER® module was utilised. 
The actuation force was set to 60 N (automatic actuation), the distance to the 
measuring zone was set to 10 cm and a spray angle of 60° (mimicking the angle in 
which a nasal spray is usually applied in vivo) was used. Measurements started at an 
optical concentration above 0.5 % and particle size distributions were measured every 
10 ms. For data extraction, a time point with steady optical concentration was chosen.  
Cumulative frequency (Q3) and probability density function (q3*), representing the first 
derivative of the cumulative frequency, were plotted. Characteristic values of the particle 
size distribution x50, x10 and x90, corresponding to the median, the 10 % and the 90 % 
quantile were used for calculation of the span, Equation (3-3).  
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ݏ݌ܽ݊ ൌ ݔଽ଴ െ ݔଵ଴ݔହ଴  
(3-3)
This value is especially useful for describing the distribution width when particle sizes 
are not normally distributed. 
 
3.4.3.3 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) pictures were taken to visualise obtained 
microparticles and especially particle surface. In comparison to optical microscopy it 
allows a higher resolution suitable for particles in a low µm-range achieving 
magnifications up to 100 000-fold. A bundled electron beam is accelerated and directed 
onto the sample surface. Depending on the interactions between the sample and the 
electrons, different signals can be detected, including the emission of secondary 
electrons. Those can be received by a detector and used for the creation of an image 
after scanning a previously defined area of the sample surface [106].  
Analysis of non-conductive samples, such as mannitol, often leads to build up of 
electrostatic charge. To be able to analyse those samples, their surface is covered with 
an electrically conductive layer. For this purpose the samples are fixed onto carbon 
stickers and sputtered with a Bal-Tec SCP 050 Sputter Coater (Leica Instruments, 
Germany) for 65 s to generate a thin gold layer on them. SEM pictures were taken with 
a Zeiss Ultra 55 Plus (Carl Zeiss, Germany) at a working voltage of 2 kV; signals were 
recorded from secondary electrons by an SE-2 detector. 
 
3.4.4 Determination of Zeta Potential 
The assessment of zeta potential (ZP) is especially important for samples that are solely 
stabilised by electrostatic charge (in comparison to sterically stabilised suspensions). By 
means of the ZP, the stability of such samples can be estimated. Suspensions with a ZP 
above +30 mV or below -30 mV are expected to be stable [107]. NPs produced in this 
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study were stabilised electrostatically. Hence, the ZP of the produced nanosuspensions 
and the redispersed NiM was evaluated. 
As depicted in Figure 3-11 the ZP is the potential measured at the slipping plane. It must 
not be confused with the surface or the Stern potential, which is the potential at the 
margin of the first layer adhered to a particle. An electrical double layer exists around 
every particle [102]. 
 
Figure 3-11. Distribution of potential around a charged particle, adapted from [102]. 
 
3.4.4.1 Laser Doppler Velocimetry 
The ZP can be calculated from the electrophoretic mobility of a nanosuspension. It can 
be obtained by performing an electrophoresis experiment and determine the particles’ 
velocity (proportional to measured fluctuation intensity of scattered light) by Laser 
Doppler Velocimetry. The ZP can be calculated from the electrophoretic mobility using 
the Henry equation (Equation (3-4), taken from [102]). 
ܷா ൌ 2ߝ ൈ ߞ ൈ ݂ሺ݇ܽሻ3ߟ  
(3-4)
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ζ stands for the ZP, UE represents the electrophoretic mobility, ε the dielectric constant 
and η the viscosity. For fሺkaሻ, which denotes the Henry’s function, two values are usually 
used as approximations: either 1.5 or 1.0. If measurement is performed in aqueous 
media with moderate electrolyte concentration fሺkaሻ is assumed to be 1.5, referred to as 
Smoluchowski approximation. The value of 1.0 is used for very small particles (below 
200 nm) measured in a non-aqueous environment [102]. 
For the experiments performed within this work, the Zetasizer ZS Nano (Malvern 
Instruments, UK) in combination with folded capillary cells (Malvern Instruments, UK) 
was used. A potential is applied to the electrodes at both ends of the cell, thus charged 
particles move towards the electrode with opposite charge. Moving particles scatter 
light which is detected at an angle of 17° and combined with the reference beam. This 
fluctuating signal can be correlated to the speed of the particles [102]. ZP 
measurements were performed with a diluted nanosuspension in a ratio of 
nanosuspension to ultrapure water of 1:1 exhibiting conductivity below 1 mS cm-1. 
Consequently, the viscosity of water has been used for the calculations, confer Equation 
(3-4). Measurements were started after an equilibration time of 60 s at a temperature of 
25 °C. The measurement consisted of three runs without a delay in between; ten single 
measurements were performed in each run. 
 
3.4.5 Characterisation of Interaction between Chitosan and CMC 
Particle formation by ionic gelation is a spontaneous self-assembly of used substances. 
Hence, it is desirable to employ techniques that allow an understanding of particle 
formation and differences in particle formation depending on the excipients. 
 
3.4.5.1 Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) is a calorimetric technique that can be used to 
study interactions between molecules exploiting the fact that every reaction either 
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absorbs or releases energy. Traditionally, this technique is used to study interactions 
between a macromolecule (e.g. a protein) and a small ligand. 
The experimental setup (Figure 3-12) consists of two cells (sample and reference) in an 
adiabatic jacket. Both cells are kept at exactly the same temperature. A syringe is 
inserted in the sample cell. 
 
Figure 3-12. Images show the ITC experimental setup. The picture on the left shows the 
reference (A) and the sample cell with the syringe (B). The cells are placed in an adiabatic 
jacket allowing to work at isothermal conditions. Peltier elements between the cells 
measure heat differences after each titration step. The picture in the middle shows 
exemplary raw data for an exothermic reaction, each injection is represented by a peak. 
The picture on the right gives an exemplary result curve indicating the reaction’s 
stoichiometry and enthalpy. 
If a reaction takes place, the resulting energy change between the sample and the 
reference cell will be measured indirectly as the differential power applied to bring the 
two cells to the same temperature again [108]. Exothermic events thus result in negative 
and endothermic events in positive values for applied differential power. A great 
advantage of ITC is that it is a label-free technique so that the interactions can be 
studied between unmodified substances. Labelling of a substance might change its 
reactivity and hence the measured differential power. 
Both, sample and reference cell, consist of an inert material, such as hastelloy or gold. If 
aqueous solvents are used, the reference cell is filled with ultrapure water. It is 
absolutely necessary to have the exact same solvent in sample cell and syringe to avoid 
large signals superposing the examined reaction by buffer mismatch. To ensure efficient 
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mixing, the syringe that serves simultaneously as stirrer is spirally formed. The 
concentration in the sample cell is usually lower than the concentration in the syringe 
because only low volumes are applied in each step. One titration step consists of 
approximately 1 - 25 µL [109], depending on the size of the sample cell. Generally, it can 
be said, the more titration steps have been performed, the weaker the reaction because 
more and more material already reacted. At some point the reaction is complete and 
instead of binding between the substances only dilution effects can be recognised. Data 
that can be gained from ITC experiments includes information about the interaction 
potential of two substances, the stoichiometry of a reaction and thermodynamic data as 
enthalpy and entropy which are decisive for a reaction to happen spontaneously. This is 
the case if the change in Gibb’s energy G	 is negative. Equation (3-5) gives the 
influencing parameters on the Gibb’s energy: The enthalpy H, the temperature T and 
the entropy S. 
∆ܩ ൌ ∆ܪ െ ܶ ൈ ∆ܵ (3-5)
Two different ITC devices were utilised in this study, namely the MicroCal VP-ITC and 
the MicroCal PEAQ-ITC (both Malvern Instruments, UK). Both instruments have coin-
shaped cells consisting of hastelloy. They can be operated at temperatures between 
2 °C and 80 °C. Experiments were performed at 25 °C. The MicroCal VP-ITC has a cell 
volume of 1.4 mL and a syringe volume of 300 µL. A standard experiment consists of 35 
injections with a spacing of 200 s. The injection volume was set to 8 µL (added over the 
course of 16 s), except for the first and the last injection with a volume of 1 µL. Those 
two data points are not included in the final evaluation. The first injection is used to 
prime the syringe for the first injection that is evaluated. Moreover, a stirring speed of 
307 rpm has been used. Data evaluation was performed with the Origin Software 
(Malvern Instruments, UK). The MicroCal PEAQ-ITC has a cell volume of 200 µL and a 
syringe volume of 40 µL. A standard experiment here consists of 19 injections (spacing 
of 150 s) with an injection volume of 2 µL (added over the course of 4 s) each. A priming 
injection that is not included in final evaluation is done as well with a volume of 0.5 µL. 
42 Materials and Methods 
 
 
Stirring speed was set to 750 rpm. Data was evaluated with MicroCal PEAQ-ITC analysis 
software (Malvern Instruments, UK). 
 
3.4.6 Determination of Protein Content 
Proteins can be quantified by different techniques, such as fluorescent, spectroscopic or 
colorimetric methods. Fluorescent methods are based on self-fluorescence of amino 
acids, mostly of tryptophan which can be excited at 280 nm and subsequently emits 
light at 320 - 350 nm. Spectroscopic methods measure the tryptophan’s absorption at 
280 nm or the absorption of peptide bonds at 205 nm. While fluorescent and 
spectroscopic methods in general have the advantage of keeping the protein in its 
natural state, colorimetric methods allow a higher sensitivity as they are based on 
chemical reactions but concurrently are destructive. Nowadays, colorimetric methods 
are widely used [109]. Many different colorimetric assays can be applied; most of them 
can be obtained commercially. Usually they are either based on protein-dye binding or 
protein-copper chelation reactions. Depending on the sample and the accompanying 
substances (e.g. buffer salts), the best suited assay should be chosen [110]. In this study, 
the Pierce™ BCA Protein Assay Kit and the Micro BCA™ Protein Assay Kit (both Thermo 
Fisher Scientific, USA) with linear measuring ranges of 20 - 20 000 µg mL-1 and 
0.5 - 20 µg mL-1, respectively, were used. This assay is an example for protein-copper 
chelation reactions, as depicted in Figure 3-13. It was first developed by Smith et al. in 
1985 [111]. Advantages of the bicinchoninic acid (BCA) assay include its linear response 
curve, an incubation time of 30 min (making time difference while pipetting samples 
into a 96 well micro test plate negligible compared to e.g. incubation of 5 min for a 
Bradford assay) and its compatibility with up to 5 % detergents [110]. 
Materials and Methods 43
 
 
 
Figure 3-13. Reaction mechanism for the BCA assay in alkaline medium, adopted from 
[110]. 
This assay is a good choice for experiments in this study among the many available 
because it does not detect free amino groups but relies on the reducing capacity of a 
protein leading to a colour change from green to purple. An assay depending on free 
amino groups might give false positive results because chitosan exhibits free amino 
groups that could react in such an assay as well. 
Determination of protein loading was performed indirectly by measuring the protein 
concentration in the supernatant after centrifugation of the NPs and precipitation of 
chitosan with NaOH. Subsequent dilution with 10x phosphate buffered saline (PBS) was 
intended to bring the samples’ pH to 7.4. This way prepared samples were pipetted into 
96 well micro test plate and freshly prepared BCA reaction mix was added. A 30 min 
incubation time at 37 °C was followed by a cool-down phase of another 30 min at room 
temperature. Afterwards the absorption values were measured with a plate reader 
(FLUOstar® Omega, BMG LABTECH, Germany) at a wavelength of 562 nm. Each 
measurement was executed in quadruplicate, results are given as mean. 
44 Materials and Methods 
 
 
The loading efficiency LE was calculated based on the non-encapsulated protein in the 
supernatant in comparison to the total amount of protein using Equation (3-6). 
ܮܧ ൌ 1 െ ݊݋݊ െ ݁݊ܿܽ݌ݏݑ݈ܽݐ݁݀ ݌ݎ݋ݐ݁݅݊ݐ݋ݐ݈ܽ ݌ݎ݋ݐ݁݅݊ ൈ 100 % 
(3-6)
The loading capacity LC was calculated based on the non-encapsulated protein in the 
supernatant in comparison to the total amount of particle forming excipients using 
Equation (3-7). 
ܮܥ ൌ ݐ݋ݐ݈ܽ	݌ݎ݋ݐ݁݅݊ െ ሺ݊݋݊ െ ݁݊ܿܽ݌ݏݑ݈ܽݐ݁݀ ݌ݎ݋ݐ݁݅݊ሻݐ݋ݐ݈ܽ	݌ܽݎݐ݈݅ܿ݁ ݂݋ݎ݉݅݊݃ ݌݋݈ݕ݉݁ݎ ൈ 100 % 
(3-7)
 
3.4.7 Determination of Hygroscopicity 
Dynamic vapour sorption (DVS) was used to determine whether the developed NiM 
formulation was hygroscopic. It is a gravimetric technique, measuring the amount of 
solvent absorbed to and desorbed from the sample as a function of the relative vapour. 
Commonly, water vapour is used to adjust the relative humidity, but it is also possible to 
use organic solvents. DVS cannot only be used for investigation of hygroscopicity as 
done in this project but furthermore for, e.g. investigating polymorphism [112]. 
DVS measurements were performed using a DVS-Resolution (Surface Measurement 
Systems, UK) working at isothermal conditions (25 °C). To begin with, the sample 
(approximately 30 mg) was dried at a relative humidity of 0 %, and then the humidity 
was raised in 10 %-steps to 90 % and decreased again. The next humidity step was 
initiated if no significant change in mass (< 0.0005 % min-1) was measured. This first 
cycle was followed by a second one to investigate whether irreversible events took 
place in the first cycle. 
The hygroscopicity of the material was determined based on the weight increase of the 
powder at the end of the 80 % rH-step in the first cycle and classified according to the 
European Pharmacopoeia (Ph. Eur.). 
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3.4.8 Aerodynamic Characterisation 
Assessing the in vitro aerodynamic performance of an inhalation formulation by 
performing an impaction analysis is a very common method. Such impaction analyses 
can be performed with the Next Generation Impactor (NGI, Copley Scientific, UK) which 
is described in the Ph. Eur. as apparatus E [113], depicted in Figure 3-14.  
 
Figure 3-14. Image on the left shows the closed NGI connected to a 2 L nasal expansion 
chamber. On the right the scheme of the opened NGI with the seven stages and the MOC 
at the bottom and the respective nozzles in the lid can be seen. 
The principle behind all impactors is the inertial deposition of the particles. The 
aerosolised formulation is sucked through the impactor or, more precisely, through a 
series of stages comprising nozzles with decreasing diameter. Depending on a particle’s 
or droplet’s characteristics it will deposit on a stage when it cannot follow the airstream 
anymore due to inertia. Any remaining particles will be deposited in the micro-orifice 
collector (MOC). Depending on the flow rate, the aerodynamic particle diameter cut offs 
can be calculated for each stage [114]. From those results the FPF, referring to the 
percentage of particles with an aerodynamic diameter below 5 µm, was calculated with 
the Copley Inhaler Testing Data Analysis Software (Copley Scientific, UK). The FPF is 
interesting if examining nasal products because when designing these, the aim is to 
obtain a predominantly nasal deposition and at the same time to keep the FPF as low as 
possible (due to regulatory requirements). 
To assess nasal deposition, two different settings were chosen: the NGI in combination 
with the 2 L nasal expansion chamber (Figure 3-14, left) which is intended for nasal 
powders or a nasal cast (Figure 3-15), which is used without a connected NGI as well. 
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The nasal cast model (Boehringer Ingelheim, Germany) is based on a CT scan obtained 
from a male adult. It is divided into five segments: nostrils, nasal vestibule, lower 
turbinates, middle/upper turbinates and nasopharynx. Using the nasal cast, the regional 
deposition in the nose can be determined. 
 
Figure 3-15. Images of opened nasal cast (left) depicting the modular setup of the nose 
model and nasal cast connected to the NGI (right). 
All stages of the NGI and nasal expansion chamber or nasal cast were coated with a 
mixture of 1,2-propanediol (Sigma-Aldrich, USA) and 2-propanol (AppliChem, Germany) 
prior to measurement to avoid particle bouncing. For experiments with the nasal cast 
only, no air flow was applied. If the NGI was utilised (both in combination with nasal 
expansion chamber and nasal cast) it was operated at a flow rate of 15 L min-1. This flow 
rate corresponds to the normal breathing rate of an adult. If the nasal cast was used 
two doses of NiM powder (40 mg) instead of one (20 mg) were applied by means of the 
UDS powder. After actuation(s) the flow was stopped and all components were 
separated and flushed with modified 10x PBS to obtain the samples. A D-mannitol assay 
(chapter 3.4.9) was used to quantify the obtained samples. 
 
3.4.9 Quantification of Nano-in-Microparticles 
NiM concentration in samples was quantified with a D-Mannitol Assay Kit (Abnova, 
Taiwan) as they mostly consist of mannitol. The assay is based upon the enzymatic 
reaction of mannitol dehydrogenase with D-mannitol converting it to D-fructose in the 
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presence of NAD being converted to NADH itself. NADH reduces a colourless molecule 
to a chromogen which can be detected at a wavelength of 450 nm [115]. 
Samples (dissolved in modified 10x PBS) were pipetted into a 96 well micro test plate. 
Calibration solutions were prepared with NiMs from the same batch as the samples. 
Both, samples and calibration solutions, were then mixed with assay buffer and the 
reaction mix prior to incubation for 20 min at 37 °C. Afterwards plates are left at room 
temperature for 30 min to allow cooling. Absorption at 450 nm was then measured with 
a plate reader (FLUOstar® Omega, BMG LABTECH, Germany). 
 
3.4.10 Cell Culture 
Experiments were performed at the Institute for Experimental Cancer Research at Kiel 
University and University Hospital of Schleswig-Holstein at Campus Kiel in Kiel, 
Germany. 
Dendritic cells for in vitro uptake experiments were generated via elutriation from 
monocytes from healthy donors’ blood monocytes following established protocols [116]. 
Written consent was obtained from all donors. After 5 d of differentiation culture, FITC-
conjugated NiM powder was resuspended in a concentration of 2.1 mg mL-1 in culture 
medium and 100 µL of this suspension were added to the DCs (approximately 350 000 
cells per mL per well). After 24 h of incubation, cells were washed with phosphate 
buffered saline, harvested with Accutase (Sigma-Aldrich, USA), washed again and then 
either analysed by flow cytometry (FACScalibur, BD, USA) or by image-cytometry 
(ImageStream®x Mark II, Merck, Germany). 
Collected flow cytometry data was analysed with WEASEL Flow Cytometry Software 
(Frank Battye, Australia). A first gating step was performed to identify living cells. This 
was done by plotting side- against forward-scattering (correspondent to granularity and 
size of the cells, respectively). The gate was set in a manner to exclude cell debris and 
particles not associated with cells. In a second step, the FITC+ cells, correspondent to 
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cells associated with NPs, were identified by plotting the FITC signal against the forward 
scatter and setting the gate by means of a negative control (cells without NP treatment). 
By using image-cytometry an internalisation score (INS), the ratio of intra- to 
extracellular signal of interest (FITC-tagged NPs), could be determined. Following 
membrane counterstaining with anti CD11c-APC (BioLegend, USA) the NPs could be 
localised in- or outside the cell. A negative INS indicates extracellular localisation while a 
positive INS indicates intracellular localisation. 
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4 Results and Discussion 
In the following chapter, the results obtained in this project are presented and 
discussed. First, the production and characterisation of NPs consisting of chitosan and 
two different counterions are described, followed by those particles’ ability to be loaded 
with the model protein OVA. Then, the development and characterisation of a dosage 
form (dry powder) for those NPs are described. Towards the end, the results of first in 
vitro uptake experiments are provided. 
 
4.1 Production and Characterisation of Nanoparticles Consisting of Chitosan and 
Carboxymethylcellulose 
In this work the particle formation method for NP consisting of chitosan and sodium 
carboxymethylcellulose (CMC) as adapted from Diedrich [92] was further examined to 
gain a deeper understanding of the process. Schematically shown in Figure 4-1, it is 
based on the fact that the two polymers are contrarily charged and self-assemble as 
NPs upon mixing. The key part of it is a charge neutralisation of the free amino and 
carboxyl group. As each polymer (chitosan and CMC) has multiple free amino or 
carboxyl groups, respectively, this charge neutralisation takes place many times 
between two or more polymer strands resulting in a cross-linking of those. 
 
Figure 4-1. Scheme of the particle formation process between chitosan and CMC due to 
ionic binding between positively charged amino group and negatively charged carboxyl 
group. 
In the following, influencing parameters on the process and their effects on the NPs 
have been investigated. NPs used as antigen carrier in mucosal vaccination should have 
a size suitable for preferential uptake in DC of at most 500 nm, as described in 
chapter 2.2.1.1. 
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Beneath the particle size, other parameters are crucial for the NPs, first of all particle 
stability. Moreover, the used chitosan quality, the mechanism of interaction, the 
addition sequence, the usage of stabilisers and the loading of a protein may have an 
impact on the resulting NPs and their size. Hence, those are discussed in the 
subsequent chapters as well. 
 
4.1.1 Particle Stability 
NPs with a ZP above +30 mV or below -30 mV are known to be stable in case that they 
are solely stabilised by charge and not (additionally) by steric configuration. To assess 
whether the stabilisation can be primarily ascribed to the electrostatic stabilisation, the 
ZP of obtained nanosuspensions was tested. If the nanosuspension agglomerated, 
when the ZP drops below +30 mV or rises above -30 mV, it can be used as stability 
indicator. 
The measured ZP is highly dependent on the solvent used for the measurement. Hence, 
a dilution of the suspension might lead to a change of absolute value. On the other 
hand, dilution might also lead to less variance in data. Hence, in this project, an 
experiment to assess the effect of dilution on the absolute value and variance of ZP was 
performed utilising nanosuspensions that were diluted with water to different ratios. The 
results (Figure 4-2) indicated that a dilution of 1:2 with water should be preferred 
because, while resulting in almost the same absolute ZP value, the relative standard 
deviation (RSD) in between three performed runs was decreased substantially. This 
dilution has been used for all subsequently performed ZP measurements. 
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Figure 4-2. Diagram on the left shows the absolute ZP values for the different dilutions 
(numbers indicate the rate of dilution, n = 3, error bars = SD) while diagram on the right 
gives the RSD derived from the measurements. 
To assess the likely stability of NPs, rising amounts (0.5 mL-steps) of a 0.1 wt% CMC 
solution were added to 5 mL of 0.1 wt% chitosan and the resulting ZP and size were 
determined for each nanosuspension. Results are depicted in Figure 4-3. 
 
Figure 4-3. Particle size and PDI values (left) as well as corresponding ZP (right) are 
displayed for the experiment with chitosan 90/10c. Black circles () and bars () 
correspond to the solvent 2 % HAc for chitosan, grey circles () and bars () to 1 % HAc. 
The dotted line in the right diagram corresponds to aforementioned stability limit (above 
+30 mV) of electrostatically stabilised NPs (n = 1). 
Results showed that the particle size decreased while adding more CMC and then 
increased drastically at some point (sizes exceeded 1 000 nm). The same was true for 
0
10
20
30
40
50
60
Ze
ta 
po
ten
tia
l, m
V
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
RS
D o
f 3
 su
bse
qu
en
t Z
P 
me
asu
rem
en
ts
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0
100
200
300
400
500
600
700
800
900
1000
0 5 10
PD
I (b
ars
)
Z-a
ver
ag
e, n
m 
(do
ts)
Volume of added 0.1 wt% CMC to 5 mL 
of 0.1 wt% chitosan, mL
0
10
20
30
40
50
60
70
0 5 10
Ze
ta 
po
ten
tia
l, m
V
Volume of added 0.1 wt% CMC to 5 mL 
of 0.1 wt% chitosan, mL
52 Results and Discussion 
 
 
the PDI values. The drastic increase in size and PDI could be observed in the reaction 
vessels as sedimenting agglomerates. Visual inspection moreover showed that the 
turbidity of the nanosuspension (confer chapter 4.1.5.3) increased with every titration 
step indicating more and more particle formation before sedimentation resulted in a 
clear supernatant. This sedimentation due to instability of the nanosuspension was at 
the same time as the drop of the corresponding ZP below +30 mV. Thus, it can be 
assumed that the NPs are foremost stabilised by charge. 
An explanation for decreasing particle size when adding more CMC might be higher 
cross-linking between polymers that results in smaller, denser and/or more NPs. 
Furthermore, the influence of the acid strength becomes apparent in Figure 4-3. Particle 
size was slightly lower and the ZP dropped earlier below +30 mV if 1 % HAc was used. 
The resulting higher ZP values if the higher acid concentration of 2 % as opposed to 1 % 
was used were reasonable as more ions were present for electrostatic stabilisation. 
In Figure 4-4 and Figure 4-5 it becomes apparent that the chitosan quality is decisive 
for NP formation as well. Figure 4-4 shows the resulting particle sizes and PDI values 
subject to the utilised chitosan quality. 
 
Figure 4-4. Particle sizes and PDI values for titration experiments with three different 
chitosan qualities (75/10, 90/10c, 90/50) (n = 1). 
The particle size was positively correlated with the molecular weight of the chitosan, 
given here as viscosity. The different particle sizes of chitosan qualities 75/10 and 90/10c, 
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exhibiting the same nominal viscosity of 10 mPa s, can be explained by the varying 
actual viscosities reported in the certificates of analysis: 11 mPa s and 14 mPa s. This 
difference in viscosity accounted for the slightly different particle sizes of those two 
chitosan qualities (chitosan 90/10c resulting in larger particle sizes than chitosan 75/10). 
Chitosan 90/50 in contrast resulted in larger particles. The decrease in particle size with 
increasing CMC addition, however, was more pronounced. Details on the topic of 
particle size dependency on the chitosan quality can be found in chapter 4.1.4. 
 
Figure 4-5. Corresponding ZP for titration experiments with three different chitosan 
qualities (75/10, 90/10c, 90/50). The dotted line in the right diagram corresponds to 
stability limit (above +30 mV) of electrostatically stabilised NPs. Red boxes indicate two 
stable ratios for NPs (n = 1). 
The ZP results show another picture. There was no difference observable for those 
chitosan qualities exhibiting a similar degree of deacetylation (DDA, 90/10c and 90/50) 
while the chitosan with lower DDA (75/10) deviated in behaviour. This quality resulted in 
generally lower ZP. This led to unstable NPs at lower CMC concentrations compared to 
higher deacetylated qualities. The variation in size and ZP caused by the acid strength 
used for dissolution of chitosan prior to particle formation, which was shown for 
chitosan 90/10c (Figure 4-3), could be observed for the other qualities as well (data not 
shown). For further experiments two stable weight ratios of chitosan to CMC have been 
chosen: 1:1 and 2:3, as indicated in Figure 4-5. To summarise, it can be said that while 
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the molecular weight primarily influences the size of the particles, the DDA is crucial for 
particle stability. 
 
4.1.2 Mechanism of Interaction Between Chitosan and Carboxymethylcellulose 
ITC has been employed to gain a deeper understanding of the binding mechanism 
between chitosan and CMC during particle formation. This was done to determine 
whether differences observed in particle formation described in the previous chapter 
(4.1.1) as well as the impact on the size could be confirmed or even further confined. 
Compared to many other techniques, ITC holds the great advantage of working label-
free. Thus, the actual particle formation process can be re-enacted and no labels alter 
the polymers resulting in a different particle formation. ITC works by injecting very small 
volumes (syringe) into a larger volume (cell). This is contrary to the standard 
experimental setup where two solutions in the same concentration were mixed in either 
equal volumes (ratio 1:1) or at least in similar dimensions (ratio 2:3). The concentrations 
of the excipients were adapted to fit the experimental setup of the ITC. The 
concentration of the polymer in the syringe (CMC) needed to be increased (0.9 wt% 
instead of 0.1 wt%) due to the small injected volume and to increase the concentration 
gradient even further the polymer in the cell (chitosan) was only dissolved to a 
concentration of 0.05 wt% instead of 0.1 wt%. Gradients of approximately 20 are 
recommended as starting conditions for ITC experiments and proved suitable for the 
following experiments. Those were performed with the three chitosan qualities 
previously discussed: 75/10, 90/10c and 90/50. Figure 4-6 delineates the resulting 
titration curves. Due to time constraints, the experiments could only be performed once. 
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Figure 4-6. Binding curves for titration experiments with different chitosan qualities (cell) 
and CMC (syringe) as a function of the weight ratio between the two polymers (CMC to 
chitosan). The chitosan qualities showed differences in binding affinity varying the DDA 
and no difference varying molecular weight (n = 1). 
Differences in particle forming process became obvious utilising ITC. Higher DDA led to 
a higher extent of chitosan reacting (curve is shifted to the right), probably leading to a 
higher particle yield (refer to chapter 4.1.5). Additionally, the particle formation 
mechanism changes, as indicated by the changed enthalpy. This was probably due to 
the changed amount of free amino groups available for reaction changing the cross-
linking between the polymers. No influence of molecular weight on the particle forming 
process could be shown (curves for chitosan qualities with a DDA of 90 % look alike). By 
these trials the previous results (ZP values) from the particle preparation experiments 
could be confirmed. Higher DDA results in more (and intense) particle formation, even 
at small scale. No statement about expected size could be made based on the ITC 
experiments. 
To gain further insights into the mechanisms that govern particle formation, the titration 
of CMC into chitosan 75/10 was repeated with the PEAQ-ITC. Here, the software not 
only calculated the binding curves but also created the so-called signature plot (Figure 
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4-7) which indicates whether a reaction is driven by change in enthalpy or by the 
product of entropy and temperature. While the value for the change in enthalpy can be 
taken directly from the experimental data, the Gibb’s energy and entropy are calculated 
by the software. The course of a reaction is favoured if all values in the signature plot 
are negative [108]. 
 
Figure 4-7. Signature plot from titration experiment with chitosan 75/10 and CMC 
indicating the Gibb’s energy (ΔG), the enthalpy (ΔH) and the negative value of the 
product of temperature and entropy (-T ΔS). 
The Gibb’s energy is negative, thus a reaction takes place spontaneously. The binding 
between chitosan 75/10 and CMC is mainly driven by entropy, hence by hydrophobic 
interactions. Enthalpy (corresponding to hydrophilic binding) has a value of 
approximately zero, therefore it neither favours nor opposes the reaction [108]. This was 
not to be expected as the binding between chitosan and CMC is based on ionic 
gelation. Rather, it was expected to have a reaction dominated by hydrophilic 
interactions. The change in entropy might be related to the orientation change of 
polymers (coiled vs. straight) and hence different interaction with surrounding medium 
which result in large changes in entropy which are not dominated by hydrophobic 
interactions. Using this analysis tool of the PEAQ-ITC software allows interesting insights 
that would not have been obtainable by other techniques. However, for a deeper 
understanding of the thermodynamics further experiments (e.g. different chitosan 
qualities and temperatures) will be needed.  
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4.1.3 Addition Sequence 
This subchapter examines to which extent the addition sequence (adding CMC to 
chitosan or vice versa) had an influence on the resulting NPs. That the addition 
sequence influences particle size has already been shown in a previous project [92]. 
The titration experiments performed within chapter 4.1.1 were repeated in an almost 
identical fashion, the only difference being that now chitosan was added to CMC. While 
the nanosuspensions obtained after adding CMC to chitosan showed an initial decrease 
in particle size as well as PDI and agglomeration if the corresponding ZP dropped 
below +30 mV (Figure 4-3), the nanosuspensions resulting from chitosan into CMC 
titration gave different results, shown in Figure 4-8. 
 
Figure 4-8. Particle size and PDI values (left) as well as corresponding ZP (right) are 
displayed for experiment with chitosan 90/10c. CMC was dissolved in water. The dotted 
lines in the right diagram correspond to stability limits (above +30 mV or below -30 mV) 
of electrostatically stabilised NPs (n = 1). 
Negative ZP values were expected and measured for particles with only little addition of 
chitosan because the CMC dissolves as polyanion in water. However, the ZP was 
above -30 mV and rose continuously, indicating unstable NPs. All nanosuspensions that 
received up to 6.5 mL of chitosan formed agglomerates until the next day, even when 
the ZP indicated stable particles (above 3 mL addition of chitosan). This was probably 
due to the ZP change during particle formation resulting in unstable particles even 
though the final ZP indicates stable particles (above +30 mV). Measured sizes for NPs 
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were overall larger than in the reverse addition sequence (CMC into chitosan) and 
constantly increasing which was probably also a consequence of the ZP change from 
negative to positive. In contrast, if titrating CMC into chitosan the ZP was positive from 
the beginning and therefore led to overall more stable particles until ZP dropped below 
+30 mV. 
To overcome this problem of changing ZP during particle formation, in another 
experiment it was tried to keep the ZP always below -30 mV. Here, the solvent for CMC 
was changed from water to PBS expecting particle stabilisation by keeping the ZP 
below -30 mV due to higher salt concentration and buffer capacity. Figure 4-9 depicts 
the respective results. 
 
Figure 4-9. Particle size and PDI values (left) as well as corresponding ZP (right) are 
displayed for experiment with chitosan 90/10c. CMC was dissolved in PBS (n = 1). 
The expected effect of lowering ZP by adding PBS did not materialise. Particles were 
overall a little more stable, showing agglomeration only for those samples with an 
addition of 2 - 3 mL chitosan solution. Particle sizes were a little lower if CMC was 
dissolved in PBS instead of water. This hints at a favourable effect of salt concentration 
on particle formation. Nonetheless, titrations of CMC into chitosan where CMC was 
dissolved in PBS were not performed within this project due to time constraints. Future 
projects should however keep this option in mind. 
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Altogether, from these experiments it can be summarised that the addition sequence 
influences the particle formation. If CMC was added to chitosan, resulting particles were 
smaller than if reversing this step. For comparison, the results for the previously selected 
stable ratios (1:1 and 2:3) are depicted in Table 4-1.  
Table 4-1. Particle characteristics from titration experiments with chitosan 90/10c 
(dissolved in 2 % HAc) giving the values for ratios 1:1 and 2:3. 
Ratio Addition sequence Z-average, nm PDI ZP, mV 
1:1 
CMC (water) added to chitosan 325.0 0.181 56.1 
Chitosan added to CMC (water) 662.7 0.298 51.6 
Chitosan added to CMC (PBS) 523.6 0.316 43.8 
2:3 
CMC (water) added to chitosan 271.6 0.185 44.9 
Chitosan added to CMC (water) 780.3 0.280 54.4 
Chitosan added to CMC (PBS) 561.6 0.249 45.5 
The most likely explanation for this difference is the “passing” of the unstable ZP range 
(-30 mV to +30 mV) during particle formation introducing instability along the way. 
Other possible explanations include the differences in molecular weight of the 
participating polymers, charge density and/or orientation (linear vs. coiled polymer 
strands). The difference in molecular weight is unlikely because the particle formation 
process does not seem to be influenced by the varying molecular weight of the chitosan 
(further information on that topic can be found in chapter 4.1.2). The influence of the 
charge density cannot be distinguished because the exact charge density of the used 
CMC quality was not tested and the charge density of chitosan was varied. As also 
shown in chapter 4.1.2 the particle formation process generally is influenced by the 
charge density (hence, the DDA) resulting in lower enthalpy with lower DDA. 
Nevertheless the overall decreasing particle size if adding more CMC to chitosan is 
independent of the used chitosan quality. Therefore, this difference probably does not 
account for the differences occurring after changing the addition sequence. The 
influence of the orientation of the polymer cannot be assessed because no experiments 
were performed to determine it. 
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The results in this chapter showed that the addition of CMC to chitosan appears more 
suitable for formation of stable NPs in the desired size range. The lower particle sizes 
achieved by this addition sequence go along with smaller PDI values and thus, a 
narrower size distribution, which is also favourable. Following these results, adding CMC 
to chitosan was used in all successive experiments. 
 
4.1.4 Particle Size 
As the particle size is thought to be crucial for uptake in cells this chapter shows the 
influence of chitosan quality and chitosan to CMC ratio on the particle size. For this 
purpose, NPs were formed with numerous chitosan qualities in the selected stable ratios 
under standard experimental conditions. Particle sizes and respective PDI and ZP values 
obtained are shown in Table 4-2. 
Adding CMC slowly (e.g. slow addition through a syringe or slow pouring from a 
beaker) was important for all nanosuspensions. If the CMC was added at once, particle 
size increased (data not shown). This increase with fast CMC addition was probably due 
to less time for NP formation. 
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Table 4-2. Particle size, PDI and ZP measured after particle formation with various 
chitosan qualities (n = 3, for clarity no standard deviation (SD) values were included). The 
chitosan qualities are ordered from top to bottom by rising viscosity. 
Chitosan 
quality 
Ratio 1:1 Ratio 2:3 
Z-average, 
nm PDI ZP, mV 
Z-average, 
nm PDI ZP, mV 
90/10b 248.1 0.162 44.9 139.4 0.128 34.2 
85/10 277.0 0.141 47.1 188.1 0.128 36.7 
75/10 327.5 0.155 47.1 254.5 0.182 34.4 
90/10c 351.9 0.191 51.9 252.8 0.186 41.7 
90/10a 352.0 0.240 49.1 321.7 0.400 40.0 
95/10 328.2 0.230 48.3 269.3 0.328 36.7 
90/20 403.3 0.230 54.4 337.2 0.257 42.5 
70/20 439.1 0.223 45.3 285.4 0.221 33.9 
80/20 456.4 0.235 50.1 322.2 0.243 36.4 
80/50 555.8 0.258 51.9 376.4 0.300 35.2 
70/50 531.6 0.281 46.8 332.5 0.254 32.5 
90/50 687.9 0.322 56.8 536.8 0.386 43.1 
90/200 986.1 0.375 58.6 620.9 0.324 46.9 
ZP values showed that all obtained nanosuspensions were stable. Generally, ZP was 
lower if more CMC was used in particle formation. The same tendency could be 
observed for size and PDI corresponding to the results from the first titration 
experiments (4.1.1). Size could be tuned by using different molecular weight chitosan 
(see Figure 4-10, chitosan qualities were ordered according to their molecular weight). 
The molecular weight (or as given for the chitosan qualities used: the viscosity) is 
positively correlated with particle size and PDI. To reach the targeted particle size of 
maximal 500 nm the viscosity should be kept below 50 mPa s (corresponding to an 
average molecular weight of approximately 150 kDa). The DDA on the other hand did 
not influence the particle size as much (see Figure 4-11, chitosan qualities were ordered 
by their DDA). Here, no trend with rising DDA could be observed. To summarise, with 
this production method for NPs only the molecular weight is decisive for particle size, 
while the DDA does not need to be considered. 
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Figure 4-10. Particle sizes measured after particle formation with various chitosan 
qualities which are ordered by rising viscosity and CMC (n = 3, error bars = SD). 
 
Figure 4-11. Particle sizes measured after particle formation with various chitosan qualities 
which are ordered by rising DDA and CMC (n = 3, error bars = SD). 
 
4.1.5 Quantification of Nanoparticles 
NPs are formed by ionic gelation in this study. Preliminary experiments showed that 
only a share of the particle forming excipients (chitosan and CMC) actually form NPs: If 
FITC-conjugated chitosan (appears yellow) is utilised for particle formation and the 
formed NPs were centrifuged down, the supernatant still had a yellow colour, which 
indicates that free chitosan is present. Thus, it is important to quantify the amount of 
obtained NPs to assess the impact of chitosan quality, counterion and used ratio on 
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particle yield and to calculate the protein to particle ratio (particle loading) if a protein is 
encapsulated. Another option would be to indirectly quantify the amount of NPs by 
quantifying the non-reacted part in the supernatant. It is, however, not only relevant to 
know the total particle yield but moreover the proportions of both particle forming 
polymers present in the NPs to further understand and optimise the particle formation 
process. 
 
4.1.5.1 Ninhydrin Assay 
The quantification of chitosan is challenging because it is a natural polymer exhibiting 
not one defined molecular weight or DDA but a distribution of both values. 
Furthermore, its functional groups are free amino groups which are present in proteins 
as well making a distinction between chitosan and protein challenging. The easiest way 
for quantification of a polymer is via its functional groups. Hence, within this project, it 
was first attempted to quantify chitosan via its free amino groups. This method however 
would only be suitable for quantification of chitosan in NPs produced without protein 
because it could not be distinguished between those two. Nonetheless, to get an idea 
of the amount of chitosan involved in the particle formation of placebo NPs it seems a 
suitable method. In literature the ninhydrin assay is mentioned as a potential method 
for quantification of chitosan [117–119]. Usually it is used to quantify proteins or amino 
acids. The reaction of ninhydrin with primary amino groups forms a purple dye, which is 
called Ruhemann’s purple after Siegfried Ruhemann who first described it [120]. 
Before this assay can be used, however, it must be tested whether the DDA and 
molecular weight of the chitosan involved in the particle formation remain unchanged 
because this is crucial for the applicability of the ninhydrin assay [117]. Therefore, an 
experiment determining the DDA and the molecular weight before and after particle 
formation was conducted. Unchanged DDA and molecular weight would be taken as 
evidence that the assay can be applied to calculate the concentration of chitosan 
involved in particle formation. 
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For the experiment chitosan before and after particle formation was needed. For the 
“pre” chitosan the raw material was used. As “post” the chitosan which was present in 
the supernatant after NP formation was used. To obtain it, NPs with three different 
chitosan qualities (75/10, 90/10c and 90/50) and CMC (ratio 1:1) were produced, 
centrifuged and the supernatant was skimmed off. The excess chitosan in the 
supernatant was precipitated using NaOH. The precipitated chitosan was washed via 
centrifugation. Subsequently, the obtained “post” chitosan was dried for 48 h in a 
vacuum drier. Only if the characteristics of the “pre” and “post” chitosan stay unchanged 
it can be concluded that the share which formed NPs complies with the raw material. If 
there is any change it can be concluded indirectly which share reacted and conclusions 
from that include if particles preferentially form with higher or lower deacetylated and 
molecular weight chitosan. 
The DDA was assessed by 1H-NMR, examples for obtained spectra of chitosan 75/10 
before and after particle formation are shown in Figure 4-12 and Figure 4-13, 
respectively. 
 
Figure 4-12. 1H-NMR spectrum of chitosan 75/10 starting material with integrals of 
different H-Atoms. Integrals (H-1D = 1.000 and H-Ac = 0.6659) were used to calculate the 
DDA. 
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Figure 4-13. 1H-NMR spectrum of chitosan 75/10 after particle formation with integrals of 
different H-Atoms. Integrals (H-1D = 1.000 and H-Ac = 2.1021) were used to calculate the 
DDA. 
Results for all measured samples are summarised in Table 4-3. All samples showed 
lower DDA values after in comparison to before particle formation. 
Table 4-3. Integrals and calculated DDA for examined chitosan qualities before and after 
particle formation (n = 2, ± min/max, 90/10c “post” n = 1 due to experimental reasons). 
Chitosan 
quality 
Before/after 
particle formation 
Integrals Calculated 
DDA H-1D H-Ac 
75/10 Before 1 0.6429 ± 0.0230 82.4% After 1 2.4087 ± 0.3066 55.5% 
90/10c Before 1 0.2531 ± 0.0077 92.2% After 1 1.8388 62.0% 
90/50 Before 1 0.2919 ± 0.0577 91.1% After 1 3.9823 ± 0.0122 43.0% 
The DDA of the “post” chitosan was lower for all examined qualities. Hence, the part of 
the chitosan with a higher DDA reacted to form particles. The more reactive chitosan 
was the higher deacetylated share of the distribution probably due to the higher 
availability of free amino groups. This effect was independent of the absolute value of 
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the DDA of the “pre” chitosan. These results already show that the ninhydrin assay is not 
suitable for determining the amount of reacting chitosan in this NP formation method 
because the DDA does not stay the same which would have been a crucial prerequisite 
for the applicability. 
However, in order to complement the determination of the DDA, the molecular weight 
before and after particle formation was measured as well. This addressed two questions. 
First, is the molecular weight after particle formation still the same as before? And 
second, if not is the underlying molecular weight distribution monomodal or are 
different fractions present that possibly disappear completely after particle formation? 
The same samples prepared for the determination of the DDA were used for the 
following experiments. SEC coupled with two different detectors was used to determine 
the molecular weight: a multiple angle light scattering (MALS) and an RI detector. The 
MALS detector does not need calibration but depending on the scattering (measured at 
90°) gives the molecular weight directly. On the other hand, the RI detector must be 
calibrated with a standard (in our case: pullulans) and then not only gives the 
hydrodynamic volume, but moreover how much of the substance elutes at a given time. 
This becomes obvious in Figure 4-14. While the MALS detector showed different molar 
mass fractions, the RI detector indicated that only one fraction (retention volumes 
between 12 mL and 15.5 mL) corresponded to the mass of the examined chitosan. 
Consequently, only the MALS peak corresponding to the mass fraction was used for 
determination of molar mass. The other peaks probably correspond to impurities which 
were not further examined. 
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Figure 4-14. SEC chromatogram of chitosan 75/10 before particle formation. Dots indicate 
the scattering detection (MALS detector) at an angle of 90°, while the line depicts the 
mass fraction recorded by the RI detector. The MALS signal at 10.5 min and the RI signals 
at approximately 20 min and 26 min can be ascribed to HAc which served as solvent. 
The molecular weight was either determined by taking the mean retention volume (of 
the complete RI peak width) and calculating the hydrodynamic volume from it or by 
using the scattering signals of the MALS detector for the peak corresponding to the 
mass fraction (RI detector). The results are given in Table 4-4. Due to time constraints, 
the experiments were only performed once. 
 
Table 4-4. Molecular weight for examined chitosan qualities before and after particle 
formation calculated as hydrodynamic volume or molar mass (n = 1). 
Chitosan 
quality 
Before/after 
particle formation 
Hydrodynamic 
volume, kDa 
Molar mass, 
kDa 
75/10 Before 81.4 82.3 After 57.1 62.2 
90/10c Before 77.9 133.1 After 60.6 71.0 
90/50 Before 106.4 140.7 After 94.2 96.5 
The values for hydrodynamic volume and molar mass agree for some samples, but not 
for all. This is probably due to reactions with the column materials decreasing the 
hydrodynamic volume. Nonetheless, the overall trend is similar for both evaluation 
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methods: the molecular weight of “post” is lower than that of “pre” chitosan. Hence, the 
higher-molecular-weight-chitosan preferably reacts to particles and the lower share of 
the distribution remains in the supernatant. This phenomenon is, as has been seen 
before for the DDA, independent of the starting molecular weight. No separate 
fractions of molecular weight which correspond to distinguished mass fractions could 
be found for the examined chitosan qualities. Each sample showed one peak which 
simply slightly shifted to the right after in comparison to before particle formation. 
Based on those experiments, the determination of DDA and molecular weight, it can be 
concluded that the ninhydrin assay is not suitable to calculate how much chitosan has 
reacted. If the amount of chitosan reacted was determined by a ninhydrin assay and 
would be indirectly calculated by determining the concentration in the supernatant, it 
would be overestimated (lower DDA than the reference would give less intensive 
colouring in the assay). 
 
4.1.5.2 Anthrone Assay 
The previous chapter showed that a usable assay must work independently of chitosan’s 
DDA and molecular weight. The anthrone assay is based on the detection of glucose 
units, deeming it a suitable technique to quantify chitosan regardless of DDA and 
molecular weight (because always the same mass instead of the same molar 
concentration was used). Moreover, the CMC could be quantified by this assay as well 
as it consists of glucose units as well. 
By incubation with concentrated sulphuric acid the polymers are split into monomers 
which further react to form a furfural. This forms a colourant with anthrone. The 
underlying reaction is shown exemplarily for glucose (1) in Figure 4-15. 
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Figure 4-15. Reaction steps of the anthrone assay with glucose, taken from [121]. 
By incubating glucose with concentrated sulphuric acid it reacts to 
hydroxymethylfurfuraldehyde (2). This product condenses with anthrone (3) if heated 
and forms 10-[5-hydroxymethylfuranyl)methylene]-anthrone (4) which gives a green 
colour [121]. 
Different experimental conditions were tried for chitosan quantification. In the following 
the final conditions are briefly described: Chitosan was dissolved in 1 % HAc and mixed 
with the same volume anthrone reagent (0.75 g anthrone (Merck, Germany) dissolved in 
a mixture of 17 mL water and 83 mL of 96 % sulphuric acid (Carl Roth, Germany)) in a 
2 mL-microtube and incubated for 30 min in boiling water. After cooling with ice, the 
absorption at 578 nm was measured. Resulting calibration curves with chitosan qualities 
75/10, 90/20 and 90/50 are shown in Figure 4-16. 
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Figure 4-16. Calibration curves of chitosan qualities exhibiting various DDA values and 
viscosities with the anthrone assay (n = 2, error bars = min/max). 
The green colour resulting with chitosan was very light as indicated by rather low 
absorption values between 0.005 and 0.1 for concentrations from 0.1 mg mL-1 to 
1 mg mL-1, which might possibly be due to incomplete degradation of chitosan. 
Nonetheless, the coefficients of correlation were satisfactory with values of 0.9855, 
0.9947 and 0.9781 for chitosan qualities 75/10, 90/20 and 90/50, respectively. 
As mentioned before, CMC consists of glucose units as well. Therefore, it was tried 
whether it reacts in the anthrone assay as well before a further look was taken into the 
applicability of this assay for NP/excipient quantification. The sample preparation was 
similar, with the exceptions that water was used as solvent for CMC and the incubation 
time was reduced to 7 min. The resulting calibration curve (coefficient of determination 
of 0.9993) is shown in Figure 4-17. As can be seen by the absolute absorption values, 
the colour development was more pronounced for CMC. The anthrone assay develops 
different colours subject to the sample, analysing CMC gave a dark blue colour. 
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Figure 4-17. Calibration curve of CMC with the anthrone assay (n = 1). 
In this chapter it was shown that both used polymers can be quantified using the 
anthrone assay. If they reacted similarly the assay could be used for a determination of 
the overall polymer in the NPs. Nevertheless, both polymers show a different behaviour 
in the assay. That is why they must be separated in order to quantify them correctly. For 
that purpose the NPs were centrifuged and the supernatant skimmed off to quantify the 
excess amount of chitosan and CMC in it. Chitosan was precipitated with 1 M NaOH. 
The supernatant still containing the excess CMC was separated from the pellet. The 
chitosan containing pellet should have been dissolved in dilute acetic acid prior to 
analysis. The CMC in the supernatant could be used directly. Two problems occurred 
with this procedure: The pellet could not be dissolved and the separation by 
centrifugation was not complete. This became obvious after performing an anthrone 
assay with the supernatant. Instead of the blue colour a mixed one developed indicating 
that chitosan was still present in the sample. Therefore, it could be concluded, that even 
though a method for detection of chitosan and CMC was developed, no quantification 
could be performed due to a lack of an efficient separation technique. Nonetheless, this 
method might be used to quantify NiM, chitosan and CMC combined, in aerodynamic 
characterisation. Please refer to chapter 4.5.2 for this. 
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4.1.5.3 Alternative Methods for Quantification 
In the literature another method to quantify chitosan is discussed: Fluorescence 
measurements of excess FITC-tagged chitosan [122]. In such an experiment the chitosan 
would be labelled with FITC before the particle formation (described in 3.2.3). With this 
label the unreacted chitosan can be quantified after particle formation in the 
supernatant. This technique was however not used in this study because the particle 
formation process would have been changed. The FITC-label which would covalently 
bind to the amino groups of the chitosan would change the DDA of the respective 
quality. And changing the DDA of a chitosan alters the particle formation process 
(shown in 4.1.1) as a consequence. Determined chitosan concentration in NPs would 
only be true for particle formation with the tagged chitosan but not the raw material. 
Instead of quantifying the excipients individually other papers quantify the NP together 
by weighing the obtained NP and comparing that mass to the originally applied mass of 
excipients [123]. This method was not used because of the associated high error 
potential: contaminants in the nanosuspension, polymer not involved in particle 
formation not being discarded with supernatant or loss during drying.  
A potential surrogate for particle concentration might by the determination of the 
turbidity of the nanosuspension. This might be helpful if evaluating whether a washing 
step diminished the particle concentration. The turbidity primarily depends on the 
number of particles present, but is, in addition, also to some extent determined by their 
size. The size varies, as explained earlier, with the ratio between chitosan and CMC as 
well as the chitosan quality used. Consequently, the measurement of transmission to 
quantify turbidity is not a reliable parameter but can be used as an indicator to get a 
basic understanding of different particle yields, e.g. higher turbidity if more counterion 
was used signifying a higher particle yield. 
This means that no method to quantify the NPs properly could be found in this project. 
Future projects should address this topic as it is important to know the particle yield to 
calculate e.g. a particle load and compare it to find the best ratio of antigen to carrier 
(particles). 
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4.1.6 Stabiliser Addition 
As mentioned before, prepared NPs are only stabilised electrostatically. The following 
experiments tested whether the introduction of steric stabilisers further stabilises the 
nanosuspension which could allow the addition of even more CMC (e.g. in a ratio of 
chitosan to CMC of 1:2) potentially leading to higher particle yields, potentially even to a 
complete particle formation. 
Three different chitosan qualities (75/10, 90/20 and 90/50) in three different ratios of 
chitosan to CMC (2:3, 2:4 and 2:5) were utilised. The different stabilisers polyvinyl 
alcohol (PVA), hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) 200, 
Poloxamer 188 and polysorbate 80 were dissolved to a concentration of 1 mg mL-1 
either in the chitosan phase or in the CMC phase. The concentration of 100 wt% 
stabiliser in relation to the polymer concentration was chosen because it is a very high 
concentration under which an effect would be expected, if there was one. This has been 
shown in previous projects [124,125]. All other parameters were kept the same: chitosan 
and CMC were dissolved to a concentration of 1 mg mL-1 in 2 % HAc and water, 
respectively, and CMC was added to chitosan. Using the 2:3-ratio NPs could be formed, 
nonetheless, this ratio was stable without addition of stabilisers as well. Here, no 
substantial effect on particle size could be observed for any tested stabiliser. With the 
other two ratios (2:4 and 2:5) no stable nanosuspensions could be obtained at all – 
irrespective of the used stabiliser. Agglomeration took place for all chitosan qualities, no 
matter whether the stabiliser was added to the chitosan or the CMC phase (data not 
shown). This straightforward method of introducing the stabiliser to the particle 
formation process was not successful. It is likely that the stabilisers did not adsorb to the 
outer surface of the particles but were included in the particles during particle formation 
and hence not able to sterically stabilise the outer surface. The later addition of the 
stabiliser to previously formed particles might allow for a better stabilisation. Still, the 
main goal of these trials, adding more counterion to increase the particle yield, could 
not be achieved. Therefore, this approach was not followed up by further experiments. 
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If future experiments necessitated sterically stabilised particles, the potential of 
subsequent addition of stabiliser to a nanosuspension should be reconsidered. 
 
4.1.7 Scalability of Batch Size 
The standard batch size used in this project was 10 mL. Since this was a rather low 
volume and further applications of the nanosuspension (further processing to NiMs, 
chapter 4.4, or for in vitro experiments, chapter 4.6) will require larger batch sizes, the 
effect of batch size on resulting particle size was examined. The particle size was not 
strongly affected by batch size. Even relatively large batch sizes of up to 300 mL could 
be produced in the same size range, confer Figure 4-18. Particles consist of chitosan 
90/20 and CMC in a ratio of 2:3 including 1 mg mL-1 OVA in the starting chitosan 
solution (encapsulation experiments are described in chapter 4.3). 
Common to all batch sizes was the importance of slow CMC addition that was already 
mentioned earlier (4.1.4). 
 
Figure 4-18. Particle size distributions resulting from two different batch sizes (as indicated 
in the legend) resulting in z-averages of 215 nm and 234 nm for batch sizes 10 mL and 
300 mL, respectively (data of one representative experiment). 
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4.2 Production and Characterisation of Nanoparticles Consisting of Chitosan and 
Deoxycholate 
In addition to CMC another counterion was used within this project for comparison: 
sodium deoxycholate (DOC). It was used in a previous project to form NPs as well [126]. 
DOC is a promising excipient for NPs as antigen carriers in vaccination because bile salts 
are known to interact with membranes, increasing their permeability which might lead 
to improved uptake of the formulation [79,127]. Within this project the goal was to 
compare the two counterions regarding their ability to form NPs. The most prominent 
differences are their molecular weight (0.4 kDa for DOC compared to approximately 
90 kDa for CMC) and their amount of charges per molecule (one for DOC compared to 
multiple charges for CMC). 
 
4.2.1 Development of Particle Formation Method 
A particle formation method similar to that of chitosan and CMC was developed instead 
of utilising the one developed earlier [126] for better comparison of the utilised 
counterions and their effect on particle formation. The previous method was based on 
dissolving chitosan in acetic acid. But prior to the particle formation water and PBS 
buffer at pH 7.4 were added and the solution was adjusted to a pH of 5.5. DOC 
(dissolved in water) was subsequently added to the chitosan phase resulting in a 
concentration of 0.4 mg mL-1 of each substance in the final nanosuspension. 
For the new method, the same weight concentrations of the excipients, which were 
used for the NPs consisting of chitosan and CMC, were tried. In first trials chitosan was 
dissolved in different solvents (either pure 1 % or 2 % HAc, corresponding to pH values 
of 2.6 and 2.7, respectively, or 1 % HAc adjusted to higher pH values (3, 4 and 4.5) with 
1 M NaOH) to a concentration of 0.1 wt%. DOC was dissolved in water to 0.05 wt% and 
0.1 wt%. Results are displayed in Figure 4-19 (0.1 wt% DOC) and Figure 4-20 (0.05 wt% 
DOC). 
76 Results and Discussion 
 
 
 
Figure 4-19. Particle size and PDI values obtained from nanosuspensions formed with 
chitosan 90/10c dissolved to 0.1 wt% in different solvents (indicated by column) with 
0.1 wt% DOC (n = 2, error bars = min/max). 
 
Figure 4-20. Particle size and PDI values obtained from nanosuspensions formed with 
chitosan 90/10c dissolved to 0.1 wt% in different solvents (indicated by column) with 
0.05 wt% DOC (n = 2, error bars = min/max). 
All combinations resulted in stable nanosuspensions (no agglomeration occurred after 
combination of the substances). Overall, the particles formed with 0.1 wt% DOC were 
larger (up to 500 nm) than those with 0.05 wt% DOC (up to 300 nm) but concurrently 
the nanosuspensions were more turbid if utilising 0.1 wt% DOC, indicating more particle 
formation. In between the different solvents, the same trends could be observed for 
both DOC concentrations. Particles formed with 2 % HAc were larger than those with 
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1 % HAc. And utilising a chitosan solution at pH 3 gave larger particles than those at 
pH 4 and 4.5 (particle sizes comparable to those produced with chitosan dissolved in 
1 % HAc without further alteration of the pH). 
Particle formation with DOC probably mostly relies on the charge equalisation and 
hence decreased solubility. DOC only has one charge per molecule, therefore effective 
cross-linking cannot take place. Depending on the present salts and pH values this 
results in differently sized particles. If more DOC was present more chitosan charges 
could be equalised and hence more particles could be formed. In comparison to NP 
formed with chitosan and CMC the turbidity was generally lower, indicating less particle 
formation for DOC as counterion which was probably due to the lack of cross-linking. 
For further experiments 1 % HAc was chosen as best solvent and the concentration of 
0.1 wt% for DOC because of the higher particle concentration. 
 
4.2.2 Particle Stability 
Similar to the experiments with chitosan and CMC the stability of NPs was determined 
via titration experiments. For ZP measurements a 1:2 dilution with water was chosen as 
well. Results are shown in Figure 4-21. 
 
Figure 4-21. Particle size and PDI values (left) as well as corresponding ZP (right) are 
displayed for experiment with chitosan 90/10c (dissolved in 1 % HAc) (n = 1). 
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Particle size and PDI decreased when more counterion was added to the chitosan 
solution. In contrast to titration experiments with chitosan and CMC no size or PDI 
increase, that would have indicated particle instability, could be observed up to a weight 
ratio of chitosan to CMC of 1:2. This went along with ZP values being well above 
+30 mV for all nanosuspensions. To assess the particle stability limit, further 
experiments were performed to find the ratio of chitosan to DOC where particles 
become unstable. Results of those experiments are shown in Figure 4-22. 
Even though the ratio of chitosan to DOC was extended from 1:2 (10 mL 0.1 wt% DOC 
added to 5 mL of 0.1 wt% chitosan) over 1:3 and 1:4 (7.5 mL and 10 mL 0.1 wt% DOC 
added to 2.5 mL of 0.1 wt% chitosan, respectively) to 1:10 (5 mL 0.1 wt% DOC added to 
0.5 mL of 0.1 wt% chitosan) no instability could be observed. Particle size, PDI and ZP 
stayed on the same level. Only the turbidity of the nanosuspension increased with 
increasing DOC concentration in the final suspension. 
 
Figure 4-22. Particle size and PDI values (left) as well as corresponding ZP (right) are 
displayed for experiments with chitosan 90/10c (dissolved in 1 % HAc) with higher ratios of 
DOC to chitosan (n = 1). 
Overall, particle sizes are smaller compared to particles formed with CMC which could 
be expected due to the much lower molecular weight of DOC and the lack of cross-
linking. The particle size decrease when adding more DOC was probably due to denser 
packaging of chitosan strands because more precipitated simultaneously. If both 
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polymers were used in the same concentration of 0.1 wt% very different volumes of 
chitosan and DOC phase must be taken for a ratio 1:10. Hence, it was tried to use DOC 
in a higher concentration (e.g. 1 wt%) and reduce the volume by this. But if 
concentrations above 0.1 wt% were used, agglomeration occurred after addition of DOC 
to chitosan and no NPs could be obtained (data not shown). 
No ITC measurements to study the binding between chitosan and DOC could be 
performed because no shared solvent (suitable for particle formation) for chitosan and 
DOC was found, a crucial prerequisite for this technique. 
 
4.2.3 Particle Size 
Utilising DOC as counterion it was checked as well how the particle size was influenced 
by different chitosan qualities used for particle formation. Particle sizes and respective 
PDI and ZP values obtained are shown in Table 4-5. 
Table 4-5. Particle size, PDI and ZP obtained after particle formation with various chitosan 
qualities (n = 3, for clarity no SD values were included). The chitosan qualities are ordered 
from top to bottom by rising viscosity. 
Chitosan 
quality 
Ratio 1:1 Ratio 1:5 
Z-average, 
nm PDI ZP, mV 
Z-average, 
nm PDI ZP, mV 
90/10b 204.7 0.099 51.9 148.6 0.088 47.5 
85/10 195.4 0.145 49.7 158.1 0.108 47.2 
75/10 270.5 0.141 53.8 177.3 0.113 50.3 
90/10c 235.2 0.147 52.2 165.7 0.120 48.4 
90/10a 207.3 0.162 52.5 168.6 0.128 48.8 
95/10 216.6 0.140 53.9 159.6 0.120 51.9 
90/20 255.8 0.145 53.1 167.7 0.124 48.2 
70/20 327.0 0.189 57.7 207.3 0.157 51.9 
80/20 325.8 0.194 54.2 198.3 0.160 53.2 
80/50 313.2 0.284 56.3 198.9 0.194 50.1 
70/50 404.7 0.266 61.7 225.0 0.218 51.5 
90/50 320.2 0.285 56.5 195.5 0.205 51.4 
90/200 391.6 0.489 60.6 215.0 0.270 59.1 
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Again, two different ratios were used: 1:1 (comparison to particle sizes achieved after 
particle formation with CMC) and 1:5 (stable ratio in particle formation with chitosan and 
DOC). All obtained nanosuspensions showed ZP values well above +30 mV, indicating 
stability. The particle size, PDI and ZP values were lower if more counterion was used, 
this was consistent with the effect seen for NPs consisting of chitosan and CMC. Size 
however was not predominantly governed by molecular weight as it was the case for 
particle formation with CMC. Rather, it depended on the DDA as well. Particle size was 
positively correlated with molecular weight and negatively correlated with DDA. 
Accordingly, ordering the chitosan qualities by either characteristic did not result in a 
clear trend (Figure 4-23 by rising viscosity, Figure 4-24 by rising DDA). Nevertheless, the 
size was more strongly influenced by the molecular weight (or corresponding viscosity) 
than by the DDA. 
 
Figure 4-23. Particle sizes measured after particle formation with various chitosan 
qualities which are ordered by rising viscosity and DOC (n = 3, error bars = SD). 
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Figure 4-24. Particle sizes measured after particle formation with various chitosan 
qualities which are ordered by rising viscosity and DOC (n = 3, error bars = SD). 
 
4.2.4 Comparison of Nanoparticles Consisting of Chitosan and as Counterion 
Carboxymethylcellulose or Deoxycholate 
In general, particles formed with DOC were smaller than those formed with CMC, shown 
in Figure 4-25. To reach the targeted particle size of a maximum of 500 nm all available 
chitosan qualities can be used. Using DOC could rather result in particles too small to 
be recognised as particles by cells (below 100 nm). To meet the size requirements, a 
higher molecular weight chitosan would have to be used. Whether this higher molecular 
weight would have an impact on the adjuvant potential of chitosan would be interesting 
to test. Scherließ et al. did measurements on that topic finding a comparable or even 
better immune response if a higher molecular weight chitosan was used. Nonetheless, 
these authors also varied the DDA and particle size of the chitosan. Hence, those results 
cannot be fully ascribed to the molecular weight and further tests to distinguish the 
effect are needed [128]. And if working with higher molecular weight chitosan, it must 
be kept in mind that the PDI rises (broader size distribution) as well. 
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Figure 4-25. Particle sizes measured after particle formation with various chitosan 
qualities which are ordered by rising viscosity and different counterions in a weight ratio 
of 1:1 (n = 3, error bars = SD). 
Overall, the turbidity of nanosuspensions formed with chitosan and DOC was lower 
compared to particle formation with chitosan and CMC indicating less particle 
formation. This was backed up by other trials: If NPs were centrifuged, the remaining 
pellet was smaller than after comparable particle formation with CMC or if FITC-tagged 
chitosan was utilised for particle formation almost no colour was visible in the resulting 
NPs. An explanation for this might be the low molecular weight in combination with the 
low charge density of DOC. The low charge density could not saturate chitosan 
(indicated by ZP plateau contrary to ZP drop when CMC was used) and hence could not 
form particles as efficiently. Figure 4-26 shows the resulting different particle sizes and 
ZP values subject to different ratios of chitosan to CMC. Chitosan 90/10c was utilised for 
these experiments. 
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Figure 4-26. Differences in size (left) and ZP (right) subject to utilised counterion: CMC 
(dark grey) or DOC (light grey). NPs consisting of chitosan 90/10c and CMC were not 
stable at a weight ratio of 1:2 and formed large agglomerates (above 1 µm), this is 
indicated by the truncated bar (n = 1). 
Particle sizes were generally higher and ZP values lower if CMC was utilised as 
counterion in comparison to DOC, irrespective of the utilised amount of the counterion. 
The ZP drop below +30 mV (if utilising CMC as counterion) and concurrent 
agglomeration of particles could not be observed if utilising DOC as counterion. This 
difference in ZP was probably a consequence of the lower charge density of DOC. A 
single charge per molecule is not sufficient to promote cross-linking, which resulted in a 
generally higher ZP because chitosan’s free amino groups could not be cross-linked as 
effectively. The particle formation probably solely relies on the charge equalisation and 
following precipitation of chitosan strands that coil up only coincidentally. In contrast, 
CMC can promote cross-linking due to multiple charges per molecule. 
 
4.3 Loading of Nanoparticles with Protein 
In the following chapter the loading of the NPs with proteins will be presented. OVA has 
been used as model antigen for all experiments performed in this project. Experiments 
examining the protein load of NPs were solely conducted with NPs consisting of 
chitosan and CMC because this combination results in more promising particles 
(especially higher particle yield) compared to particles formed with chitosan and DOC. 
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Preliminary ITC measurements showed that the particle formation process is affected by 
the addition of OVA to the chitosan phase. This difference is displayed in Figure 4-27. 
 
Figure 4-27. Binding curves for titration experiment with CMC (syringe) and chitosan 
90/10c containing or not containing OVA (concentration not considered in weight ratio) in 
the cell (n = 1). 
In case of OVA addition to the chitosan phase, a higher amount of CMC addition was 
necessary for the complete reaction (slight curve shift to the right). This could be 
ascribed to OVA because, by being dissolved in acetic acid, it was positively charged 
(pH below IEP of pH 4.5) and could participate in the particle formation process with 
CMC. The titration curve fluctuated more when OVA was included. A possible 
explanation for this could be more agglomeration due to the high stirring speed which 
the OVA did not tolerate as well as the chitosan and CMC. A lower stirring speed was 
however not utilised because this was necessary to ensure an instant mixing of all 
components. Evidence of OVA’s participation in the particle forming process could be 
provided by measuring a reduction in particle size compared to OVA-free counterparts. 
This is illustrated in Figure 4-28. The difference in particle size was more pronounced if 
a higher molecular weight chitosan quality was used. 
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Figure 4-28. Particle sizes of NPs formed with different chitosan qualities (using 2 % HAc 
as solvent for chitosan) and containing or not containing OVA (n = 1). 
 
4.3.1 Influencing Factors on Protein Loading 
In the following subchapters different aspects that could potentially influence the 
protein load were examined. Two different possibilities to describe the protein load are 
the determination of the loading efficiency (LE, relating to the amount of OVA used) or 
the loading capacity (LC, relating to the amount of particle forming polymer used). 
While the LE rather gives information about the efficiency of the process, the LC gives 
information about the obtained product. Hence, this value will be used primarily in the 
following chapter. Nonetheless, as described in chapter 4.1.5 the particle forming 
excipients do not completely react to form particles. As a consequence, this value 
cannot be taken as loading capacity per nanoparticle mass but per excipient mass 
(related to polymer mass in the preparation process). 
If not indicated otherwise, OVA was used in a concentration of 1 mg mL-1 in the 
following experiments. 
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4.3.1.1 Solvent 
The effect on protein load by using different solvents was studied. Chitosan 90/10a was 
thus dissolved in different acidic media, OVA was dissolved shortly before the 
experiment in the chitosan solution. HCl was tried as an alternative acid to HAc. NPs 
could only be formed if HCl was used in a concentration of 0.01 M or lower. If a higher 
concentration, e.g. 0.1 M, was used, no NP formation with chitosan (no OVA included) 
and CMC could be observed. This was due to the very low pH of below 2 of the 
resulting mixture, preventing particle formation because all polymers (including CMC) 
were positively charged and no negatively charged counterpart for particle formation 
was available. As mentioned earlier, the used acetic acid concentrations resulted in pH 
values of 2.6 and 2.7 for 2 % HAc and 1 % HAc, respectively. Moreover, an acidic buffer 
system was used for comparison, namely acetate buffer with pH values of 3.7, 4.0 and 
4.5. When using the buffer at pH 4.5, no stable nanosuspensions could be obtained (ZP 
of 29.3 mV and 15.8 mV for ratios 1:1 and 2:3, respectively), hence no LC was 
determined. Moreover, no LC could be determined for acetate buffer at pH 4.0 in the 
2:3 ratio because no stable NPs could be produced here as well (ZP of 25.0 mV). 
Resulting LCs are displayed in Figure 4-29 for different chitosan solvents. 
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Solvent 
Ratio 1:1 Ratio 2:3 
Z-average, 
nm PDI ZP, mV 
Z-average, 
nm PDI ZP, mV 
1 % HAc 169.6 0.140 43.2 142.4 0.134 36.9 
2 % HAc 168.8 0.169 45.1 148.2 0.143 37.1 
HCl 0.01 M 172.8 0.169 38.1 143.1 0.133 31.6 
Acetate 
buffer, pH 3.7 173.5 0.142 32.6 504.3 0.355 29.1 
Acetate 
buffer, pH 4.0 263.0 0.180 34.9 n.d. n.d. 25.0 
Figure 4-29. Protein LC depending on solvent for chitosan (top, n = 2, error 
bars = min/max) and respective particle size, PDI and ZP values (bottom). Parameters 
were not determined (n.d.) if agglomeration occurred. 
LC was highest for 2 % HAc with 8.07 % and 7.36 % for ratios 1:1 and 2:3, respectively. 
The values for LC are comparable for both utilised ratios of chitosan and CMC even 
though less OVA (corresponding to a lower share of chitosan starting solution in the 
final nanosuspension) was used for the ratio 2:3. Because of this, calculating the LE gives 
a slightly different result. Here, values of 16.14 % and 18.40 % for ratios 1:1 and 2:3, 
respectively, were determined. Those trends were not only true if 2 % HAc was used as 
solvent, but also for the other solvents (1 % HAc and 0.01 M HCl) as well. 
Thereupon, utilising more CMC for particle formation resulted in a higher share of 
encapsulated OVA. This was probably due to a higher share of polymers forming 
particles utilising the 2:3 ratio which were then able to encapsulate more OVA. This 
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trend could not be observed for acetate buffer at pH 3.7. Here, the NP size was 
increased substantially for the 2:3 compared to the 1:1 ratio, indicating unstable NPs. 
Hence, the calculated LCs could not be regarded as reliable. Compared to 2 % HAc, all 
other solvents gave substantially lower LCs. Consequently, this solvent was used for 
subsequent experiments. 
 
4.3.1.2 Stirring Time 
Another parameter to be investigated was stirring time, more precisely the time the 
nanosuspension was stirred after adding CMC and prior to refrigeration. OVA was 
dissolved shortly before the particle formation in chitosan 90/10a solution (2 % HAc). 
The respective particle sizes and PDI obtained after different stirring times only varied 
between 173 nm and 183 nm and 0.156 and 0.180, respectively. Thus, no substantial 
effect of stirring time on particle size could be observed. The resulting LCs after 
different stirring times are shown in Figure 4-30. 
 
Figure 4-30. Protein LC depending on the stirring time following mixing of components 
(n = 2, error bars = min/max). 
The LC decreased with increasing stirring time, from 7.01 % with no stirring after CMC 
addition to 4.08 % after 30 min stirring. This might be due to the rearrangement of the 
polymers and the protein within the NPs during stirring, excluding the OVA more and 
more over time, even though it was encapsulated during the initial particle formation. 
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The results showed no advantage of additional stirring after the mixing of the 
components. Therefore, the nanosuspensions were not stirred after addition of the CMC 
was completed. 
 
4.3.1.3 Temperature 
Experiments to study the influence of temperature on the protein load and, 
concurrently, on the particle size were performed with chitosan 90/10a. The chitosan 
and the CMC starting solutions (OVA was dissolved shortly before the experiment in 
chitosan solution which was prepared with 2 % HAc) were brought to 6, 21, 25, 30, 40 or 
50 °C, respectively. The particle formation itself was performed at room temperature. 
Results for LC and particle size are depicted in Figure 4-31. 
 
 
Figure 4-31. Protein LC depending on temperature (top, n = 3, error bars = SD) and 
respective particle size (bottom, n = 1). 
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PDI values were all below 0.2 for ratio 1:1 and below 0.15 for ratio 2:3 with the only 
exception of the particles formed with solutions at 6 °C. Here, PDI values of 0.236 and 
0.204 were measured for ratios 1:1 and 2:3, respectively. All ZP values indicated stable 
nanosuspensions giving lower values for ratio 2:3 in comparison to 1:1. Particle size 
decreased with increasing temperature probably due to lower viscosity of the solution 
and higher mobility of the polymer strands resulting in denser and smaller particles. The 
LC was positively correlated with temperature. Especially a temperature of 50 °C proved 
to be favourable. Nonetheless, for subsequent experiments ambient conditions were 
maintained, on the one hand because of practicability and on the other for protein 
stability reasons (temperature closer to melting temperature, longer residence time of 
OVA in starting acidic solution during heating). If a higher LC for a NP formulation 
however would be needed, the elevation of temperature in consideration of the stability 
of the utilised protein should be kept in mind. 
 
4.3.1.4 Chitosan Quality 
The effect of chitosan quality on protein load was studied in this trial. Chitosan phase 
with 2 % HAc as solvent was prepared with qualities varying in molecular weight and 
DDA (ranging between 75 % and 95 %). The previously used batch of chitosan 90/10 
(chitosan 90/10a) was used up. For this reason a quality with comparable characteristics 
was utilised for further experiments: chitosan 90/20. Even though the nominal viscosity 
differs, the determined values for viscosity (given by the supplier) were rather similar 
with 15 mPa s and 18 mPa s, respectively. Figure 4-32 shows the results for LC as well as 
particle size, PDI and ZP. 
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Chitosan 
quality 
Ratio 1:1 Ratio 2:3 
Z-average, 
nm PDI ZP, mV 
Z-average, 
nm PDI ZP, mV 
75/10 207.0 0.148 46.0 185.5 0.121 36.7 
85/10 185.0 0.158 48.2 181.8 0.114 37.9 
90/10c 218.3 0.178 52.0 187.7 0.144 43.4 
90/20 215.1 0.153 51.3 219.4 0.145 43.9 
90/50 343.3 0.243 57.4 268.8 0.160 46.4 
95/10 158.3 0.161 45.3 135.2 0.137 39.7 
Figure 4-32. Protein LC depending on chitosan quality used (top, n = 2, error 
bars = min/max) and respective particle size, PDI and ZP values (bottom, n = 1). 
The effect on LC by the different weight ratios of chitosan to CMC for particle formation 
which was observed earlier could be confirmed. While the DDA of chitosan did not have 
a substantial effect on the particle size of particles formed with CMC (section 4.1.4) it did 
have an influence on LC. The DDA was positively correlated with the LC. An explanation 
for this might be the presumptive higher particle yield if utilising a higher deacetylated 
chitosan quality (as presented in chapter 4.1.2) which can bind more CMC. This higher 
particle amount probably leads to higher encapsulation opportunities for the OVA, not 
only leading to a comparable LC despite the lower amount of utilised OVA but for most 
qualities even to an increased LC. All the while, no consistent effect of molecular weight 
on LC could be identified. 
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4.3.1.5 Protein starting concentration 
Based on the previous results, a new chitosan quality with favourable DDA (as high as 
possible) and viscosity (approximately 20 mPa s to meet the size requirements of 
maximal 500 nm) was purchased: chitosan 95/20. This chitosan was compared to 
qualities 75/10 and 90/20 in terms of size and protein load. All qualities exhibit a 
comparable viscosity and differ in DDA. As this was shown to influence the LC in 
previous experiments (chapter 4.3.1.4) utilising those qualities gives an overview over 
achievable LCs depending on the DDA of the starting material. The aim of these 
experiments was to assess whether the amount of OVA in the starting solution 
influenced the protein load. 
As mentioned before, the particle size depended on the protein addition. Resulting 
sizes of NPs produced with the three chitosan qualities as a function of the OVA 
addition (0 - 4 mg mL-1) are depicted in Figure 4-33. 
 
Figure 4-33. Particle sizes depending on chitosan quality used and OVA concentration 
(0 - 4 mg mL-1) in the starting solution (n = 1). 
Measured sizes for NPs made with chitosan 95/20 were approximately 250 nm if OVA 
was added. The OVA-free particles exhibited a particle size of 523 nm and 451 nm for 
ratios 1:1 and 2:3, respectively. Hence, the addition of OVA had a substantial impact on 
particle size. This impact was lower for particles formed with chitosan 90/20 and even 
less for those formed with the 75/10-quality. This effect is probably due to the varying 
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DDA and viscosity of the three chitosan qualities. The effect of particle size reduction 
was more pronounced for a higher deacetylated and more viscous chitosan. Results for 
the respective LCs can be seen in Figure 4-34. 
 
OVA concentration 
in starting solution, 
mg mL-1 
Ratio 1:1 Ratio 2:3 
75/10 90/20 95/20 75/10 90/20 95/20 
0.5 0.35 % 2.30 % 2.94 % 1.70 % 2.84 % 5.64 % 
1 4.47 % 6.73 % 10.78 % 5.03 % 7.01 % 12.53 % 
2 12.60 % 14.94 % 20.73 % 10.82 % 13.82 % 27.72 % 
4 30.69 % 38.60 % 38.57 % 24.65 % 30.71 % 49.14 % 
Figure 4-34. Protein LC depending on chitosan quality used and OVA concentration 
(0 - 4 mg mL-1) in the starting solution (n = 3, error bars = SD). 
Earlier results (comparable/higher LC/LE for ratio 2:3 compared to 1:1, higher protein 
load if higher DDA) were confirmed with this trial. For all chitosan qualities the utilisation 
of higher OVA concentrations in the starting solution resulted in higher values for the 
LC, going up to almost 50 %. This effect was mostly due to the rising amount of utilised 
OVA which is not taken into account when determining the LC. It is, if calculating the LE. 
Therefore, Figure 4-35 shows the corresponding LEs. 
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Figure 4-35. Protein LE depending on chitosan quality used and OVA concentration 
(0 - 4 mg mL-1) in the starting solution (n = 3, error bars = SD). 
Utilisation of 1 mg mL-1 OVA in the starting solution seemed favourable over 
0.5 mg mL-1. However, for the higher concentrations no further increase in LE could be 
measured for chitosan 95/20. For the other two qualities (75/10 and 90/20) a minor 
tendency of rising LE can be observed. The absolute amount of OVA encapsulated was 
increased for all qualities but most of the utilised OVA could not be loaded in the NPs. 
Therefore, if only absolute encapsulation was taken into account a higher initial 
concentration is reasonable. But, many proteins are very expensive and therefore should 
be encapsulated more efficiently. 
 
4.3.2 Alternative Addition Sequence 
In all experiments examining the encapsulation of OVA in NPs, the highest LC was 
achieved with chitosan 95/20 dissolved in 2 % HAc, giving a value of approximately 
50 % (starting OVA concentration of 4 mg mL-1). As mentioned afore, the LE was lower 
with approximately 35 %. As an LE of 35 % means that 65 % of the utilised protein does 
not associate with particles and is discarded, this would probably not be affordable in 
many cases. Therefore, another method by which the protein is encapsulated more 
efficiently was developed. 
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This new method consisted of two steps. In the first step the CMC phase (0.2 wt% in 
water) was slowly added to the OVA phase (10 µg mL-1 - 1 mg mL-1 in 2 % HAc), 
resulting in a ratio of 1:1 of the two solutions. This mixture already formed NPs because 
of the contrarily charged substances. Resulting particle sizes and corresponding LEs are 
given in Figure 4-36. Here, LEs rose with rising OVA concentration. It should however be 
noted, that the LE was not decisive here because the complete OVA-CMC mixture was 
used for particle formation, thus, the not encapsulated OVA was added to chitosan as 
well. Resulting ZPs for all OVA-CMC mixtures were approximately -14 mV. 
 
Figure 4-36. Size and LE of starting OVA-CMC mixture. 
In the second step, this OVA-CMC mixture (containing 0.1 wt% CMC and 
5 - 500 µg mL-1 OVA) was added to the chitosan phase (0.1 wt% in 2 % HAc) for final NP 
formation in ratios of 1:1 and 2:3. Not all nanosuspensions were stable. When the 
highest OVA concentration was used, NPs agglomerated regardless of which chitosan 
quality was utilised. Hence, those NPs were not further analysed. 
Figure 4-37 gives the resulting LEs for the alternative addition sequence. For the starting 
concentration of 5 µg mL-1 no reliable LE could be measured because the resulting OVA 
concentrations were below the detection limit (2 µg mL-1) due to encapsulation in the 
particles and dilution. Accordingly, if such low amounts of protein were to be 
determined another technique for quantification needed to be applied. LEs after particle 
formation with the other OVA-CMC mixtures with OVA concentrations of 50 µg mL-1 
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and 250 µg mL-1, respectively, looked very promising with values of up to 60 % or even 
70 %. 
 
Chitosan 
quality 
OVA conc., 
µg mL-1 
Ratio 1:1 Ratio 2:3 
Z-average, 
nm PDI ZP, mV 
Z-average, 
nm PDI ZP, mV 
90/20 
5 365.6 0.192 52.2 320.9 0.263 43.3 
50 330.3 0.200 51.8 293.9 0.230 42.7 
250 353.1 0.224 49.5 290.3 0.234 38.9 
95/10 
5 376.5 0.285 46.6 319.9 0.348 38.4 
50 352.5 0.255 46.9 276.5 0.282 37.7 
250 319.5 0.238 43.5 249.1 0.261 37.8 
95/20 
5 437.2 0.277 50.7 476.2 0.303 42.1 
50 425.7 0.294 50.4 365.6 0.296 42.9 
250 399.7 0.274 49.1 336.3 0.280 41.8 
Figure 4-37. Protein LE depending on chitosan quality used and OVA concentration in the 
OVA-CMC mixture (top, n = 3, error bars = SD) and respective particle size, PDI and ZP 
values (bottom, n = 1). 
Those values could not be compared to the previously used method because the 
highest concentration of 500 µg mL-1 OVA in the starting solution, which simultaneously 
was the lowest concentration used in previous experiments, did not result in stable NPs. 
Particle sizes measured were generally higher using the new addition sequence in 
comparison to the standard method described in chapter 4.3.1. This might be a 
consequence of the lower OVA concentration (confer Figure 4-33). Another explanation 
may be the sequential addition of first CMC to OVA and then OVA-CMC mixture to 
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chitosan, which completely changes the interactions during particle formation. The two-
step addition could lead to a looser binding between the polymers because many ionic 
interactions were already saturated when chitosan comes into play. 
Generally, it can be said for this trial (and the same was true for the standard method) 
that particle size decreased with increasing concentration of OVA and that particle sizes 
were lower if more CMC was utilised for particle formation (2:3 ratio instead of 1:1 ratio). 
From this trial it could be concluded that the alternative addition sequence was a 
promising approach to encapsulate OVA more efficiently. Corresponding LC values for 
the NPs are shown in Figure 4-38. 
 
Figure 4-38. Protein LC depending on chitosan quality used and OVA concentration in the 
OVA-CMC mixture (n = 3, error bars = SD). 
The LC values for a starting concentration of 250 µg mL-1 were comparable to those 
achieved with a starting concentration of 1 mg mL-1 of the standard method. Hence, less 
OVA is needed for similar LCs deeming this method promising for the efficient 
encapsulation of OVA. Future experiments need to verify whether this method can be 
transferred to other proteins. Nonetheless, as the protein is bound via ionic interactions 
to the CMC first, it will probably be transferable to other proteins as the standard 
method was transferable to other proteins, shown by Diedrich [92]. 
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4.4 Development and Characterisation of Nano-in-Microparticles 
The developed nanosuspensions were not stable for a long time und could therefore 
not be used as an application form. The stabilisation of NPs was realised by spray drying 
of the nanosuspension with a matrix (mannitol was used for this purpose) in this project. 
It led to the formation of a dry powder, which encapsulates and stabilises the NPs. The 
resulting particles were named Nano-in-Microparticles (NiM). As the powder was 
intended for nasal application, the particles must be large enough (above 10 µm) to 
deposit in the nose [31]. Hence, the fraction of particles below 10 µm should be kept as 
small as possible and the share of particles below 5 µm should be absolutely minimal 
because these particles could potentially reach the lung. To assess the aerodynamic 
behaviour of the developed formulation impaction experiments were performed (see 
chapter 4.5). 
The development of the NPs was described in the previous chapters (4.1 - 4.3). This 
chapter focusses on the development of a microparticulate dosage form. The aim was 
to develop a dosage form that can embed all different kinds of chitosan NPs. 
 
4.4.1 Design of Experiments with Mannitol 
Instead of developing a NiM formulation directly, this project focussed on the 
development of pure mannitol microparticles suitable for nasal deposition in the 
beginning due to much easier experimental conditions. In this case water could be used 
as solvent in place of a washed nanosuspension. In later experiments the transferability 
to using a nanosuspension as solvent was tested. 
The droplet size after dispersion of the fluid in the spray dryer is crucial for resulting 
particle sizes as particles will not be larger than the original droplet. To obtain particles 
suitable for nasal deposition, it is necessary to apply the ultrasonic nozzle when working 
with the lab spray dryer B-290. Using the ultrasonic nozzle larger droplets and 
subsequently larger particles (potentially suitable for nasal deposition) compared to the 
also available two-fluid nozzle could be obtained. Another advantage of the ultrasonic 
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over the two-fluid nozzle is a narrower droplet size distribution resulting in a narrower 
particle size distribution. A DoE was utilised to identify the parameters that significantly 
influence the outcome when spray drying with the B-290 in combination with the 
ultrasonic nozzle. Varied factors and measured responses of this DoE are shown in 
Table 4-6. 
Table 4-6. Factors varied in DoE and measured responses. 
Factors Responses 
Inlet temperature (110 - 150 °C) 
Feed rate (5 - 15 %) 
Mannitol concentration (5 - 20 %) 
Outlet temperature 
Particle size 
Span 
Yield 
The volume flow was not changed; it was set to 20 m³ h-1 (corresponding to 50 % 
aspirator rate), as recommended by the supplier for the ultrasonic nozzle. This rather 
low volume flow was necessary to allow a longer drying time for the larger droplets (in 
contrast to smaller droplets created with the two-fluid nozzle). Another opportunity 
would be to increase the length of the drying chamber. As this was not possible with 
the B-290, the volume flow was reduced. This simultaneously lowered the separation 
capacity of the cyclone. Smaller particles will not be separated as effectively from the air 
stream and therefore will not be collected. This reduces the yield, but it was no 
drawback within this project. It should rather be seen as a beneficial feature because, as 
explained above, the share of small particles (especially below 5 µm) should be kept as 
low as possible. The results of the DoE are given in Table 4-7. 
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Table 4-7. Varied factors and corresponding particle characteristics of powders produced 
within the framework of the DoE. 
Experiment 
name 
Run 
order 
Inlet 
temp., °C 
Feed 
rate, % Conc., % 
Outlet 
temp., °C 
Particle 
size, µm Span Yield, % 
N1 14 110 5 5 53 15.5 1.04 47.4 
N2 6 150 5 5 69 16.9 1.04 59.4 
N3 4 110 15 5 42 14.7 1.02 27.6 
N4 19 150 15 5 48 17.0 1.00 39.1 
N5 16 110 5 20 52 33.6 1.33 68.1 
N6 7 150 5 20 74 25.1 1.11 59.8 
N7 10 110 15 20 42 30.1 1.21 39.3 
N8 18 150 15 20 49 33.1 0.98 50.5 
N9 2 110 10 12.5 50 26.7 1.38 46.7 
N10 13 150 10 12.5 55 22.4 1.07 56.5 
N11 12 130 5 12.5 64 21.1 1.05 64.7 
N12 15 130 15 12.5 44 24.0 1.27 36.9 
N13 8 130 10 5 54 15.2 1.03 52.3 
N14 5 130 10 20 53 24.8 1.08 53.6 
N15 11 130 10 12.5 56 24.1 1.18 56.4 
N16 17 130 10 12.5 47 22.6 1.08 54.6 
N17 3 130 10 12.5 53 21.3 1.08 52.4 
N18 9 130 10 12.5 59 23.4 1.08 50.9 
N19 1 130 10 12.5 53 21.3 1.05 52.8 
SEM pictures of selected experiments are shown in Figure 4-39. All pictures show 
spherical, partially indented and partially broken particles. The breakage increased with 
increasing mannitol concentration. Moreover, the surface of the particles changed with 
increasing mannitol concentration to a needle-shaped rather than a smooth surface. 
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Figure 4-39. SEM images of particles created with a mannitol concentration of 5 % (N3), 
12.5 % (N15) and 20 % (N7) at 500-fold magnification. 
Model fit with values for R2 and Q2 above 0.5, model validity above 0.25 and 
reproducibility above 0.5 suggested a significant model. In line with theory, the outlet 
temperature was found to depend on inlet temperature (positively correlated) and feed 
rate (negatively correlated). Only a very slight effect of the inlet temperature (negatively 
correlated) on span could be found. The yield was generally low which could be 
ascribed to droplets sticking to the surfaces of the spray dryer instead of being dried 
and then collected in the product vessel. Because of this low yield, it was interesting to 
take a closer look at the factors that were identified to be significantly influencing 
product yield and which might change the process based on the findings. As depicted 
in Figure 4-40, it was found that all three varied factors, inlet temperature, feed rate and 
concentration, had an effect. 
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Figure 4-40. Significant coefficients (left) and model fit (right) for particle yield. 
While increasing the inlet temperature and concentration increased particle yield, it was 
reduced by raising the feed rate. This was plausible, as an increased feed rate potentially 
leads to more sticking on the surfaces a higher inlet temperature and a higher 
concentration (hence, less solvent) lead to an improved drying leading then to particles 
which can be collected. However, those parameters influencing the yield had a 
significant influence on other outcomes as well. The concentration was positively 
correlated with the particle size. The outlet temperature was significantly influenced by 
inlet temperature (positive correlation) and feed rate (negative correlation). 
The responses particle size and outlet temperature must be ranked as more important 
for the formulation than the yield. For this reason, a potentially low yield was accepted if 
the other responses were influenced favourably by a factor. The particle size was found 
to only significantly depend on the used concentration (Figure 4-41). Within this DoE 
particle sizes of up to 33 µm could be generated. The corresponding contour plot is 
given in Figure 4-42. 
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Figure 4-41. Significant coefficient (left) and model fit (right) for particle size. 
 
Figure 4-42. Contour plot of the mean particle size as a response of the significant factor 
concentration. 
All produced microparticles met the criterion of exhibiting a mean particle size above 
10 µm. Hence, the decision which concentration to use for further experiments was 
based on the share of particles below 10 µm. When a concentration of 20 % was used 
this value was below 3 % on average. For concentrations 5 % and 12.5 % the share was 
below 15 % and 5 %, respectively. Hence, a concentration of 20 % was used for the 
following experiments. 
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4.4.2 Spray Drying Large Nano-in-Microparticles 
Having obtained the results from the DoE, the development of a spray drying process 
suitable for producing NiM was the next step. Previous work showed the necessity of 
keeping the outlet temperature below 40 °C when producing NiM in order to be able to 
redisperse the incorporated NPs from the matrix upon dissolution [92]. Hence, a spray 
drying experiment with rather low inlet temperature (110 °C) at a high feeding rate 
(15 %) was taken (N7, chapter 4.4.1) and used as basis for the development of the NiM 
formulation. It exhibited an outlet temperature of 42 °C which was rather close to 40 °C. 
Repeating this experiment, moisture deposition was observed in the product vessel. This 
was due to very short drying time in the B-290. For final drying, the product was thus 
placed in a drying chamber for 5 min at 30 °C. To destroy any agglomerates, the 
powder was gently sieved through a 355 µm-sieve. Depending on the ambient moisture 
and the batch size it was possible to maintain outlet temperatures below 40 °C even if a 
feed rate of as low as 12 % was used. However, at high relative humidity in the 
environment and large batch sizes this could not be achieved. 
To obtain NiM, mannitol was dissolved in a washed nanosuspension (produced with 
chitosan 90/10a and no protein, weight ratio 1:1 of chitosan to CMC). Because of the 
high concentration of 20 % mannitol, the nanosuspension was not refilled to its original 
volume after washing but only to a tenth of it, increasing the NP concentration by the 
factor 10. Assuming a quantitative NP formation, this gave a weight ratio of mannitol to 
NP of 20:1. Obtained particles exhibited comparable morphology compared to pure 
mannitol microparticles as depicted in Figure 4-43. Only the size was decreased, 
probably due to the presence of surface active substances (chitosan, CMC) in the NPs. 
Furthermore, less breakage of particles could be seen in the SEM images for the NiMs. 
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Figure 4-43. SEM images of particles produced with a mannitol concentration of 20 % 
which was either dissolved in water (pure mannitol) or in nanosuspension (NiM with 
placebo NPs) with mean particle sizes of 36.8 ± 0.0 µm and 26.6 ± 0.1 µm, respectively, at 
250-fold magnification. 
The incorporation of placebo NPs in the microparticle matrix resulted in slightly altered 
surface morphology and size. Particles were still spherical and hollow but their surface 
appeared smoother for NiM compared to pure mannitol microparticles. This change in 
surface morphology and size was more pronounced if a protein was loaded in the NPs 
(Figure 4-44). While the surface of the pure mannitol particles appeared needle-like, the 
NiM including OVA-loaded NPs appeared smoother. However, the NiM particles were 
generally more strongly indented which is probably due to the surface activity of all 
substances that formed the NPs (chitosan, CMC and OVA). 
 
Figure 4-44. SEM images of NiM particles containing OVA with a mean particle size of 
21.1 ± 0.3 µm, at 250- (left) and 2 500-fold magnification (right). 
Overall, the particle size distribution is narrower when NPs are incorporated as can be 
seen in Figure 4-45. 
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Figure 4-45. Particle size distributions of pure mannitol microparticles and NiM (chitosan 
90/20, ratio 2:3, with OVA) exhibiting mean particle sizes of 26.9 ± 0.2 µm and 
19.9 ± 0.1 µm and shares below 10 µm of 3.3 % and 2.6 %, respectively. 
Respective span values for pure mannitol microparticles and NiM are 1.07 ± 0.04 and 
0.88 ± 0.02. Incorporating different kinds of NPs (chitosan 90/10c or 90/20 in a weight 
ratio of either 1:1 or 2:3) did not result in changed surface morphology or particle size of 
NiM (data not shown). 
As indicator for storage stability (in terms of endurance against elevated humidity) the 
hygroscopicity of this formulation was tested by DVS exemplarily. Figure 4-46 shows the 
resulting change in mass plot. 
 
Figure 4-46. DVS change in mass plot of NiM powder as function of changing relative 
humidity (water) in two cycles. Change in mass is depicted in black and the target relative 
humidity in grey (n = 1). 
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The NiM powder showed a mass change of +1.00 % in the first cycle if the relative 
humidity was raised to 90 %. When lowering the relative humidity, the formulation lost 
mass, falling even a little below its initial mass which means that the powder was not 
completely dry in the beginning. The second cycle was performed to assess any 
permanent changes in the powder by the first cycle. The powder showed a similar curve 
(maximum mass change of +0.97 %) for the second cycle indicating no changes in the 
powder. 
At 80 % rH the powder showed a mass change of +0.64 %. This can be classified as 
slightly hygroscopic (mass change of 0.2 - 2 %) according to the Ph. Eur. [129]. From this 
experiment, it could be concluded that the formulation was not sensitive towards air 
humidity. 
The obtained NiM powder appeared to be a suitable formulation in terms of particle 
size for nasal deposition and stability against humidity. Hence, follow-up experiments to 
further characterise it, regarding the redispersibility of NPs and the aerodynamic 
behaviour, were performed. 
 
4.4.3 Redispersibility of Nanoparticles from Nano-in-Microparticles 
The redispersibility of NPs from the NiM formulation is crucial for subsequent uptake in 
immune competent cells. To achieve this, not only a mild spray drying process but a 
mild washing procedure to eliminate any free excipients or protein in the supernatant 
after NP formation was conducted. If those substances were still present in the 
nanosuspension while spray drying they would probably lead to sticking of the NPs 
upon dissolution of obtained NiMs. In this project, particles were centrifuged for 
washing. Depending on the volume of the nanosuspension that was supposed to be 
washed, the centrifugation could be performed with one centrifugation step (10 mL). If 
higher volumes were to be washed (50 mL), a multiple step regime was necessary to 
avoid irreversible particle agglomeration upon redispersion. 
108 Results and Discussion 
 
 
Figure 4-47 provides an example data set of the washing procedure of a 10 mL batch 
produced in a 1:1 ratio of chitosan 90/10c to CMC indicating no substantial size increase 
before and after the washing procedure. 
 
Figure 4-47. Particle size distributions of original and washed nanosuspension exhibiting 
z-averages of 308 nm and 341 nm, respectively. 
As mentioned earlier, keeping the outlet temperature during spray drying at a 
maximum of 40 °C was necessary to maintain the redispersibility of the NPs from the 
dry powder (confer chapter 4.4.2). Figure 4-48 gives an example for NPs redispersed 
from NiM powder (300 mL batch, centrifuged as 6x 50 mL and reunited). 
 
Figure 4-48. Particle size distributions of original nanosuspension and redispersed NPs 
from NiM formulation in 1 % HAc exhibiting z-averages of 291 nm and 403 nm, 
respectively. 
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The NPs were produced with chitosan 90/20 and CMC in a 2:3 ratio. They were 
redispersed by adding 1 % HAc to the powder followed by gentle shaking. It was not 
necessary to apply strong shear forces for redispersion of NPs. An increase in z-average 
could be observed for redispersed NPs: 403 nm as opposed to 291 nm (PDI values were 
0.24 and 0.25, respectively). The particle size distribution of the redispersed NiM 
showed a second peak between 1 000 nm and 10 000 nm. In this size range the 
measurement cannot be regarded as reliable. Moreover, an intensity distribution is 
influenced by large particles particularly strongly. Therefore, it is likely that this peak is 
not related to any substantial amount of particles, but alters calculation of z-average. 
This increase in z-average was still acceptable, but future experiments should also 
address the optimisation of the washing process, especially if the 2:3 ratio is utilised for 
particle formation. Due to the higher particle yield, which probably resulted in a higher 
extent of sticking between the NPs, the washing process was not as appropriate as for 
the 1:1 ratio. 
Another thing that has to be kept in mind if it comes to in vitro uptake experiments of 
the developed NPs or rather to the NiM formulation is the redispersibility of the NPs in 
a buffer/medium suitable for the use in cell culture. If particles were redispersed in 
diluted HAc and given onto the cells the pH value would probably harm the cells. If 
particles are redispersed in a more physiological medium (PBS), in contrast to diluted 
HAc, a slight swelling of particles (probably due to the higher pH and salt 
concentration) can be observed as an increased z-average, shown in Figure 4-49 
(300 mL batch, centrifuged as 6x 50 mL and reunited). NPs for this experiment were 
produced in a 1:1 weight ratio of chitosan 90/10a and CMC. This increase must be kept 
in mind when producing NPs because it cannot be eliminated if utilising NPs obtained 
via ionic gelation from chitosan and CMC. 
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Figure 4-49. Particle size distributions of original and washed nanosuspension, 
redispersed NPs from NiM formulation in 1 % HAc and in PBS exhibiting z-averages of 
210 nm, 241 nm, 258 nm and 378 nm, respectively. 
 
4.5 Aerodynamic Characterisation of Developed Nano-in-Microparticles 
The potential of a formulation to deposit in the nose cannot necessarily be assessed by 
using the geometric particle size, determined by laser diffraction. Utilising an impaction 
analysis which takes characteristics such as density and morphology into account is 
more suitable. For example, needle-like shaped particles with a low density exhibit a 
higher geometric than aerodynamic size and hence, are less likely to deposit in the nose 
than suggested by their geometric diameter. The developed NiM formulation consisted 
of hollow particles. Consequently, the aerodynamic particle size might be lower than the 
geometric one. Potentially it could even be too low to ensure nasal deposition. Immune 
competent cells that could take up the NPs are situated throughout the mucosa of the 
respiratory tract. Hence, particles deposited in the lower respiratory tract could still be 
effective, but, for regulatory reasons, a formulation must be deposited either in the nose 
or in the lung. Accordingly, the developed formulation should deposit quantitatively in 
the nose. 
All experiments that were performed in the context of the aerodynamic characterisation 
were performed with NiM including OVA.  
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4.5.1 Dispersion from a Nasal Powder Device 
At first, the eligibility of a nasal powder device, namely the UDS powder, was tested 
regarding its dispersion ability for the powder and the powder retention in the device. 
The formulation showed no device retention which was determined by weighing the 
device before and after the shot. The resulting particle size distributions are depicted in 
Figure 4-50. 
 
Figure 4-50. The particle size distribution after dispersion via the RODOS (solid lines) and 
the SPRAYER module (dashed lines) on the left of pure mannitol particles (RODOS: 
x50 = 26.9 ± 0.2 μm, SPRAYER: x50 = 26.8 ± 0.7 μm) and on the right the corresponding 
size distributions for the NiM powder are shown (RODOS: x50 = 19.9 ± 0.1 μm, SPRAYER: 
x50 = 31.6 ± 6.7 μm) (n = 3, error bars = SD). 
The particle size distributions from dispersion via the RODOS (pressurised air, full 
dispersion) and the SPRAYER module (dispersion from device) for pure mannitol 
microparticles and NiM formulation are shown in Figure 4-50, depicting a difference 
between the two dispersion mechanisms for the NiM powder but not for the pure 
mannitol particles. This is probably due to different cohesion behaviour of the particles. 
While the spherical pure mannitol particles with a slightly rough surface were easily 
separated, the NiM could not be dispersed by the UDS powder as easily. This was 
because of indentions in the overall smooth surface which could get interlocked and 
hence are characterised by a particle size distribution which was shifted towards larger 
particle sizes showing a mean particle size of 31.6 ± 6.7 μm with a span of 1.4 ± 0.2. This 
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shift towards a larger mean particle size made the NiM powder even more suitable for 
nasal deposition. It could hence be concluded that the UDS powder device was suitable 
for the application of the developed formulation. 
 
4.5.2 Development of a Method for Quantification of Nano-in-Microparticles in 
Deposition Studies 
To assess the nasal deposition of the NiMs, a quantification method was needed. As 
usually done, it was tried to develop a method to quantify the active ingredient (in this 
case: OVA). However, no reliable quantification method could be developed. The first 
problem was the compatibility of the BCA assay (which was used for protein 
quantification before within this project) with the stage coating, which was applied to 
each stage of the NGI and the nasal expansion chamber or the nasal cast prior to each 
experiment in order to avoid particle bouncing on the hard surfaces. Depending on the 
utilised quality of 1,2-propanediol, which was used as component in the stage coating, it 
interfered with the BCA assay, probably due to impurities (reducing shares) that react 
with the BCA themselves. The problem with reducing impurities exists for mannitol, too. 
The second problem was the pH or the salt concentration of the samples. In order to 
dissolve the NPs either a strong acid (citric acid) or a high salt concentration (10 % NaCl 
in 10x PBS) was necessary. If citric acid was used, the resulting pH of the samples would 
have been too low to allow a reduction of copper by the protein. Concentrations of 
sodium chloride above 1 M (corresponding to 6 %) are not compatible with the BCA 
assay, as specified by the manufacturer. To conclude, the BCA assay could not be used 
for quantification of the protein content. 
Instead of quantifying the protein, it was tried to quantify the carbohydrate part of the 
NPs with the anthrone assay. The method developed for determining chitosan and CMC 
individually could be adapted (increased incubation time) to quantify NiM powder in a 
concentration between 0.25 mg mL-1 and 2 mg mL-1 (coefficients of determination 
above 0.98). However, the assay was also not compatible with the stage coating 
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resulting brownish colours. Figure 4-51 displays the calibration (top row) and the 
samples (rows 2 - 3). 
 
Figure 4-51. Image of microplate after performed anthrone assay showing an 
incompatibility between the assay and the stage coating resulting in brownish colours 
(rows 2 - 3) instead of light yellow-green ones (row 1). 
To overcome the challenges associated with quantifying the protein and the NPs within 
the formulation, another approach was chosen. The NiM formulation mostly consisted 
of mannitol as described earlier. Thus, it was tested to quantify the mannitol in the 
formulation by a commercially available assay that works enzymatically. Hence, no 
interferences were to be expected due to high specificity. Instead of utilising mannitol as 
calibration substance, the NiM powder was used because the exact ratio of mannitol to 
NPs was unknown because neither the concentration of excipients involved in particle 
formation nor NPs in total could be determined (please refer to chapter 4.1.5 for more 
information on this topic). The calibration in the range of 0.25 - 2 mg mL-1 gave 
coefficients of determination above 0.99. 
 
4.5.3 Nasal Deposition of NiM Formulation 
For assessment of the nasal deposition an NGI in combination with a nasal expansion 
chamber or a nasal cast was used. Usually, the NGI is used to determine the fine particle 
fraction (particles below 5 µm) in formulations intended for pulmonary delivery [113]. In 
this project it was used to show that (preferably) no fine particle fractions can be 
measured. 
The nasal deposition profile of the NiM formulation was investigated with and without 
applied airflow. If the NGI was used, the airflow was set to 15 L min-1 (impaction analysis 
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is only feasible with an applied airflow, this volume flow corresponds to normal 
breathing rate of an adult). With this airflow the cut-off diameter for the FPF of 5 µm lies 
between stage 4 (cut-off diameter 5.64 µm) and stage 5 (cut-off diameter 3.18 µm) and 
was calculated by interpolation between those two stages according to the Ph. Eur. 
[113]. 
In a first setting the deposition profile of the NiM powder in a 2 L nasal expansion 
chamber was examined. This adapter is recommended for deposition profile assessment 
of nasal sprays by the FDA [130]. The resulting deposition profile is displayed in Figure 
4-52. 
 
Figure 4-52. Deposition profile of the NiM formulation utilising the NGI in combination 
with the nasal expansion chamber at an airflow of 15 L min-1 (n = 3, error bars = SD). 
The deposition in the nasal expansion chamber was found to be 93.15 % at a recovery 
of 97.5 ± 3.4 %. An FPF of only 0.4 % was calculated from these results. Hence, the 
formulation mostly deposited in the nose as intended. 
For further characterisation of the nasal deposition profile, the nasal expansion chamber 
was replaced with the nasal cast. Apart from that, the same setup (including the airflow 
of 15 L min-1) was used. The resulting deposition profile can be seen in Figure 4-53. 
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Figure 4-53. Deposition of the NiM formulation utilising the NGI in combination with the 
nasal cast at an airflow of 15 L min-1 (n = 2, error bars = min/max). 
Ideally, a nasal powder intended for vaccination would be deposited equally over the 
nose without any deposition in nostrils and no postnasal fraction. These criteria are not 
met (depicted in Figure 4-54). Especially noticeable is the low deposition of 6 % in the 
area of the lower turbinates which is probably due to the upward administration of the 
powder resulting in more likely deposition in the upper parts of the nose. This effect 
was already described by others [131,132]. The total nasal fraction was calculated to be 
90 ± 3 % and the FPF to be 1.6 %. Generally, it can be said that the results gained with 
the NGI in combination with the nasal expansion chamber and with the nasal cast were 
in good agreement. 
Usually, a nasal powder would be applied while the patient breathes normally. In this 
project it was tried whether a patient holding his breath (no airflow applied) would 
decrease the postnasal fraction. Therefore, another experiment only using the nasal cast 
plus a cup to collect the postnasal fraction was performed to investigate the influence 
of the previously applied airflow on the regional deposition and especially on the 
postnasal fraction. The resulting nasal deposition profile was compared to the values 
obtained at an airflow of 15 L min-1 (Figure 4-54). Moreover, an ideal profile indicating 
equal distribution over all nasal surfaces excluding the nostrils is added in the diagram. 
7.43%
35.67%
6.29%
31.93%
8.56% 7.74%
0.49%0.24%0.26%0.22%0.29%0.48%0.40%
0%
10%
20%
30%
40%
50%
60%
De
po
siti
on
116 Results and Discussion 
 
 
 
Figure 4-54. Deposition of the NiM formulation utilising the nasal cast and no airflow 
(n = 3, error bars = SD) in comparison to previously gained values if NGI was operated at 
15 L min-1 (n = 2, error bars = min/max) and ideal profile. 
The comparison reveals a decreased postnasal fraction of 1.0 % (instead of 10.1 %) if no 
airflow was applied. Generally, if an airflow was applied, a shift in deposition towards the 
rear parts of the nose could be observed. The deposition in the nostrils and the area of 
the lower turbinates was comparable while especially the deposition of powder in the 
upper parts of the nose was increased with no applied airflow. This can be explained by 
exactly this – the missing airstream towards the nasopharynx. This enables the powder 
to reach the upper parts of the nose instead of being drawn through the larger internal 
openings towards the posterior parts. 
Concluding the aerodynamic characterisation experiments, it can be said, that the 
developed NiM formulation seems suitable for nasal deposition. Potential 
improvements of this formulation should aim at a lower deposition of the formulation in 
the area of the nostrils and the nasal vestibule. 
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4.6 In Vitro Uptake Experiments 
First in vitro uptake experiments were performed with the produced NPs consisting of 
chitosan and CMC. To make the particles visible in FACS and ImageStream analyses the 
chitosan was labelled with FITC prior to particle formation with CMC. 
NPs were produced with FITC-conjugated chitosan (dissolved in 2 % HAc to 1 mg mL-1) 
and CMC (dissolved in water to 1 mg mL-1). If OVA was used it was dissolved to a 
concentration of 1 mg mL-1 in the chitosan phase. NiM utilised for in vitro experiments 
were spray dried with the two-fluid instead of the ultrasonic nozzle. A lower 
concentration of mannitol (2 % instead of 20 %) and a refilling of the nanosuspension to 
its original volume after the washing was used. Refilling resulted in an identical weight 
ratio of mannitol to NPs of 20:1. The lower mannitol concentration led to much smaller 
particles of approximately 2 µm. This was done because of the higher particle yield that 
could be achieved with this setup. NPs were redispersed in cell culture medium before 
uptake experiments. For this reason, the size of the NiM was not decisive. Images of the 
NiM formulations (without and with OVA) are shown in Figure 4-55. 
 
Figure 4-55. SEM images of particles created with a mannitol concentration of 2 % which 
was either dissolved in a nanosuspension (chitosan 90/10c and CMC in a weight ratio of 
1:1) not containing or containing OVA, with mean particle sizes of 2.4 ± 0.0 µm and 
1.9 ± 0.0 µm, respectively, at 5 000-fold magnification. 
In vitro experiments were performed with the goal to assess whether the uptake of the 
NPs was concentration dependent and whether the size of the NPs influenced their 
uptake. FACS results from uptake experiments are shown in Figure 4-56. 
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Figure 4-56. Results of flow cytometric analyses of human DCs (hDCs) incubated with 
FITC-conjugated NPs (chitosan and CMC in a weight ratio of 1:1, if OVA was incorporated 
this is indicated by “OVA”) in different concentrations compared to untreated cells (ut). NP 
association is indicated as % FITC+ signal (n = 3, error bars = SD). 
The concentration of NPs added to the cells (as indicated on the x-axis) was determined 
based on the assumption that all particle-forming excipients actually formed NPs. As 
shown earlier, this is not the case (chapter 4.1.5). Therefore, those values can only be 
taken as approximations. A concentration dependent uptake could be measured for all 
particles. Moreover, a size dependency became obvious in this experiment. Larger NPs 
(formed with chitosan 90/50, approximately 1 000 nm) showed a higher association than 
smaller ones (formed with chitosan 90/10c, approximately 350 nm). Particles with 
incorporated OVA (approximately 300 nm) showed a slightly lower association than 
their OVA-free counterparts. 
Those results were unexpected. Usually smaller particles up to a size of 500 nm are 
described as being taken up to a higher extent into dendritic cells compared to 
microparticles (chapter 2.2.1.1). Further experiments were performed to verify these 
results. A concentration of 100 µg mL-1 was used for all subsequent experiments. In 
Figure 4-57 the FACS results using three different particle sizes (approximately 220 nm, 
400 nm and 1 000 nm after redispersion) are shown, confirming the previous results. 
The larger the particles, the higher the share of FITC associated cells. 
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Figure 4-57. Results of flow cytometric analyses of hDCs incubated with FITC-conjugated 
NPs (different chitosan qualities and CMC in a weight ratio of 1:1) compared to untreated 
cells (ut). NP uptake is indicated as % FITC+ signal (data of one representative 
experiment). 
In addition to the percentage of FITC+ cells (Figure 4-57, left) in the right panel of 
Figure 4-57 the median fluorescence intensity (MFI) is plotted. It indicates the brightness 
of the FITC+ cells, therefore giving an indication about the amount of FITC in the cell. 
This diagram shows an even higher increase with increasing particle size. This was to be 
expected because larger particles consist of more material which hence shines brighter. 
Nonetheless, the question remained why the results did not follow the literature. To 
investigate this question, ImageStream analyses were performed. Via imaging they 
show whether a particle is in the cell or only attached to its surface, as shown in Figure 
4-58. Results are shown in Figure 4-59. 
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Figure 4-58. Representative images of hDCs incubated with FITC-conjugated NPs 
(chitosan 90/50) analysed with ImageStream. The APC channel shows CD11c membrane 
counterstaining. Channel overlay is indicated by “+”, BF = brightfield. 
 
Figure 4-59. Internalisation score histogram of one representative experiment with FITC-
conjugated NPs (different chitosan qualities and CMC in a weight ratio of 1:1) with median 
internalisation scores (INS) of 4.95, 3.42 and 1.56 for chitosan 90/10b, 90/20 and 90/50, 
respectively. 
The results achieved by FACS analysis could be differentiated with the ImageStream 
results. The larger particles (chitosan 90/50) could be localised externally rather than 
internally, which could be described by the lower INS of 1.56 compared to 4.95 and 3.42 
for NPs with chitosan 90/10b and 90/20. This indicated increased extracellular adhesion 
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to DCs with increasing particle size despite extensive washing prior to FACS and 
ImageStream analyses. Hence, the lower uptake of the NPs containing OVA, as shown 
in Figure 4-56, can quite possibly be explained by the smaller size of those NPs reduced 
in overall uptake but simultaneously a higher level of intracellular uptake, consistent 
with the results presented for chitosan quality 90/10b in comparison to 90/20. From 
these experiments, it can be concluded that the smallest particles are best suited for 
intracellular uptake in DCs. 
Future experiments will examine the uptake of NPs in other cell types, such as 
macrophages and epithelial cells. Moreover, experiments to elucidate the uptake 
mechanisms and subsequent activation of DCs will be conducted. It is important to use 
unstained NPs for this, as the FITC-tag changes chitosan and hence particle 
characteristics. 
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5 Overall Findings, Concluding Remarks and Future Prospects 
While the experimental results achieved in this dissertation project were presented in 
the previous chapters, the following chapter provides an overall discussion of those 
results, concluding remarks and future prospects. 
The first part of the results dealt with the development and characterisation of 
nanoparticulate formulations consisting of chitosan and CMC or DOC. NPs consisting of 
chitosan and CMC could be produced in different ratios. By gradually increasing the 
amount of added CMC, the particle size could be decreased. However, at some point 
particle size started increasing dramatically (visible as agglomeration of 
nanosuspension, at a chitosan to CMC ratio of approximately 1:2). This instability could 
be correlated with the ZP. If the latter drops below +30 mV, no stable nanosuspension 
will be obtained. Two stable weight ratios (1:1 and 2:3) were picked for further 
experiments. This ZP drop was not found for NPs consisting of chitosan and DOC. ZP 
stayed above +30 mV even if utilising higher amounts of counterion. 
In literature usually penta-sodium triphosphate (TPP) is used as cross-linker for chitosan 
NPs [122,133–135]. It has five charges per molecule while exhibiting an even smaller 
molecular weight of 253 g mol-1 (without sodium ions) compared to DOC (415 g mol-1). 
Using TPP as counterion, Fan et al. [136] observed a drop of the ZP below +30 mV with 
a simultaneous increase in particle size. Therefore, the cross-linking capability can be 
ascribed completely to the availability of multiple charges per molecule rather than to 
the molecular weight of the counterion. 
The size of resulting NPs was not only governed by the ratio of chitosan and counterion 
(CMC and DOC). It also depended on the chitosan quality. Chitosan is characterised by 
its molecular weight and DDA. The molecular weight was positively correlated with 
particle size. This effect was also found by others who utilised different chitosan 
qualities for NP production [137–140]. Nonetheless, usually only one or two qualities 
were used for comparison. In this project a broader overview over achievable sizes was 
provided by using up to 14 chitosan qualities. 
Overall Findings, Concluding Remarks and Future Prospects 123
 
 
By contrast, the DDA only influences particle size to a very small extent – at least as long 
as CMC was used as counterion. However, if utilising DOC as counterion, the particle 
size negatively correlated with DDA. This effect could not be explained by the methods 
used in this project. 
Furthermore, it was not only important to measure size and ZP in order to characterise 
the NPs, but also to determine the yield of NPs. The term yield, as used in this thesis, 
signifies the amount of particle forming excipient that actually forms particles. This was 
of high interest for two reasons. On the one hand, it would allow a better assessment of 
the impact of different counterions, chitosan characteristics and utilised ratio on particle 
yield. On the other hand, it would facilitate a determination of the ratio of NPs to 
encapsulated protein. Admittedly, no reliable method for quantification of NP yield 
could be identified within this work. Nonetheless, making use of the degree of turbidity 
of nanosuspensions provided suggestive evidence about the particle yield (higher 
turbidity indicated higher particle yield). If more counterion (CMC or DOC) was utilised 
or particles were formed with CMC in contrast to DOC higher yields were achieved. 
Future projects should address the topic of NP quantification by either finding a suitable 
method to quantitatively separate the excipients (and then being able to make use of 
the anthrone assay which was found to quantify chitosan regardless of molecular weight 
and DDA) or by finding a novel technique to solve this question. 
From the results it could be concluded that CMC was the more suitable counterion. It 
was the better cross-linker and helped achieving higher particle yields. Nonetheless, 
literature describes DOC for formation of NPs with chitosan for nasal administration. 
This is due to its penetration enhancing effect on nasal absorption which might 
contribute to the functionality of NPs [79]. A recommendation to be made based on the 
experimental results in this thesis is thus that if in vitro experiments show a need for an 
absorption enhancer, a combination of CMC and DOC as counterions could be used. 
Preliminary experiments showed suitable particle sizes if CMC and DOC were each 
dissolved to a concentration of 1 mg mL-1, regardless of whether mixing took place prior 
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to addition to chitosan phase or whether CMC and DOC were added subsequently to 
chitosan phase. 
It was furthermore important to not only characterise the resulting particles, but also the 
particle formation process. For this purpose, ITC was used in this project. This 
technology was also applied by other researchers to examine differences in particle 
formation caused by different cross-linkers or different solvents [141–143]. The effect of 
the two utilised counterions could not be studied within this project because no suitable 
common solvent for ITC was found for both chitosan and DOC, a crucial prerequisite for 
ITC measurements. Hence, only CMC could be used as counterion in ITC measurements. 
In those, ITC was utilised to assess differences between various chitosan qualities used 
for particle formation. Differences were found to be based on the DDA of the respective 
chitosan resulting in a lower enthalpy and simultaneously a lower stoichiometric ratio 
for a lower deacetylated quality, which indicated an effect of DDA on the particle 
formation process. From this, it could furthermore be concluded that the DDA 
influenced particle yield (positive correlation between DDA and yield). 
Protein encapsulation experiments were only performed with NPs consisting of chitosan 
and CMC because they were regarded as advantageous over those formed with 
chitosan and DOC. In those experiments the DDA was found to substantially influence 
the protein loading of NPs. Additionally, the ratio between chitosan and CMC was 
decisive for encapsulation. A higher DDA and more added CMC were found to provide 
favourable conditions for higher LC. Other factors affecting protein encapsulation were 
the solvent and temperature. Increasing the concentration of OVA in the starting 
solution gave higher LCs but only slightly higher LEs. This meant much protein was 
discarded. The maximum LE was found to be 35 % (corresponding to an LC of almost 
50 %) for chitosan 95/20 dissolved in 2 % HAc and with a chitosan to CMC ratio of 2:3 
at ambient temperature. 
As these results left room for optimisation, a new method for protein encapsulation was 
developed. Instead of dissolving the OVA in the chitosan phase shortly before particle 
formation (standard method), it was dissolved in 2 % HAc and then mixed with CMC. 
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This mixture was in a second step used as counterion for particle formation. Here, the 
highest values achieved for LE were 60 - 70 % (corresponding to an LC of approximately 
8 %) with chitosan qualities exhibiting a DDA of 95 %. Such LCs were achieved with the 
standard method only if a higher OVA concentration of 1 mg mL-1 was used in the 
starting solution. This method has so far only been tested with OVA. Future experiments 
should expand the developed method to other proteins to assess its general feasibility. 
Depending on the goal, to encapsulate most of the protein (expensive and effective, 
alternative addition sequence favourable) or achieve a rather high LC (inexpensive 
and/or less effective, standard method favourable) one of the described methods 
should be chosen. It should however be kept in mind for both methods that proteins 
are not as stable in an acidic medium as in buffer. Nonetheless, within this project 2 % 
HAc was chosen as solvent because it was necessary for chitosan dissolution. The 
concentration of 2 % over 1 % was chosen because it was favourable for protein 
loading. The residence time in acid should be kept to a minimum and if one works with 
a sensitive protein 2 % HAc might be an inappropriate solvent and an alternative must 
be selected. 
To transfer the developed NPs to a dry powder, spray drying with a matrix was utilised. 
Prior to this, the nanosuspension was washed because not all starting substances 
formed NPs. Washing of the nanosuspension was performed via centrifugation. 
However, depending on the particle size and their amount (larger and higher), particle 
sizes tended to increase over the course of this procedure. An optimisation of this 
process would be advisable in future projects to not affect the original particle size by 
this step at all. 
Mannitol was used as matrix in spray drying in this project. This method not only makes 
the NPs applicable but stabilises them as well, which is also reported in the literature 
[123,144,145]. Depending on the deposition target of the formulation, the size must be 
adapted. Particles with a size suitable for nasal deposition could be obtained utilising 
the lab spray dryer B-290 in combination with the ultrasonic nozzle and a mannitol 
concentration of 20 wt%. Particles appeared hollow and had an overall smooth but 
126 Overall Findings, Concluding Remarks and Future Prospects 
 
 
slightly indented surface. This appearance was dependent on the incorporation of OVA 
in the NPs or not. It was however not further influenced by the kind of NPs incorporated 
(used chitosan quality or ratio between chitosan and CMC). The scheme of the NiM 
formulation proposed in the objectives was adjusted accordingly (Figure 5-1). 
 
Figure 5-1. Scheme of a produced NiM. 
NiM particles had a geometrical size of approximately 20 µm. Larger particle sizes might 
be better suited for nasal deposition. They could be obtained if inlet and outlet 
temperatures and/or higher matrix concentrations were used for the process. However, 
as a low outlet temperature (maximum of 40 °C) was necessary to ensure redispersibility 
of NPs this could not be tried within this project. A second reason why it was not 
possible to produce larger particles is that mannitol cannot be dissolved to a higher 
concentration in the aqueous solvent. Nonetheless, the obtained particles meet the 
> 10 µm requirement. DVS measurements showed only slight hygroscopicity of the 
powder making it a suitable dosage form for nasal administration. 
The aerodynamic characterisation was particularly important for the developed 
formulation. The geometric diameter measured by laser diffraction suggested a size 
suitable for nasal deposition. But because particles were hollow, the aerodynamic 
behaviour might have deviated from expectations based on the assumption of solid 
particles of this size. It could however be shown that approximately 90 % of the 
formulation was deposited in the nose. The regional nasal deposition was further 
Overall Findings, Concluding Remarks and Future Prospects 127
 
 
investigated using a nasal cast. Results showed a preferential deposition in the upper 
and anterior parts of the nose due to the upward application of the powder, which is 
typical for this device. This effect was also found by others [131,132] who examined the 
nasal deposition of dry powders. A lower share in the upper parts of the nose and a 
generally more uniform distribution over the mucosa would be favourable in order to 
maximise the potential uptake in immune competent cells. Nonetheless, the results 
indicate an almost exclusive deposition in the nose, which was aimed for. It must 
however be kept in mind that the experiments were only in vitro experiments with a 
nasal cast which probably does not adequately mimic the complex physiology 
(flexibility, ciliae) of the human nasal cavity. Therefore, those results only have 
suggestive character [21]. 
In vitro experiments were performed examining the uptake into DCs of redispersed NPs. 
They showed a positive correlation between concentration as well as size and uptake. 
The higher uptake of larger particles (1 000 nm) could be differentiated via ImageStream 
analyses. Those particles were adhered to the outer surface of the cell, rather than being 
internalised. The internalisation of particles was negatively correlated with particle size. 
Future experiments will deal with the uptake mechanisms and subsequent activation of 
the DCs. 
 
Overall, this work contributes to the deeper understanding of forming NPs with chitosan 
via ionic gelation. Influencing factors on particle characteristics were identified. 
Incorporating the NPs in a matrix made them suitable for nasal application. 
Aerodynamic characterisation showed a predominantly nasal deposition. The 
redispersed NPs can be taken up into immune competent cells but in the presence of 
epithelial cells, particles are rather taken up into those. Hence, optimisation of NPs, e.g. 
immune attractive additives such as pattern recognition ligands or cytokines to NPs or 
matrix, should be further examined. Future experiments should moreover investigate 
the activation of APC by those particles. A review by Bahamondez-Canas and Cui 
published in 2018 stressed the need for new effective vaccine formulations, especially 
128 Overall Findings, Concluding Remarks and Future Prospects 
 
 
those for nasal administration [28]. Dry powder formulations are ascribed favourable 
properties as improved patient compliance and possible self-administration. However, 
until now, no dry powder for nasal vaccination is registered. Consequently, it can be 
concluded that this dissertation project was and future research on this topic will be 
timely and topical. 
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6 Summary 
Nanoparticles (NPs) have been identified as a promising carrier and adjuvant system in 
mucosal vaccination. Chitosan is widely used as excipient for NPs for this purpose. To 
make such NPs applicable as dry powder, they can be incorporated into a 
microparticulate matrix (Nano-in-Microparticles). For an efficient nasal deposition of 
those microparticles, they should exhibit a particle size above 10 µm. Upon deposition 
the microparticulate matrix should release the NPs in their original size. The range of 
suitable sizes for an uptake of the NP in immune competent cells, especially in dendritic 
cells, is between 100 nm and 500 nm, as known from literature. 
This work focussed on the preparation and characterisation of the NPs. They were 
prepared from chitosan and carboxymethylcellulose. Ovalbumin was used as model 
antigen. The particle formation between the two polymers is based on cross-linking via 
ionic gelation (charge equalisation between the positively charged chitosan and the 
negatively charged carboxymethylcellulose). Effects on particle stability, particle size and 
protein encapsulation were tested. NPs in the range between 100 - 500 nm could be 
produced. The model antigen could be loaded in the NPs, depending on the method 
used rather high loading efficiencies of up to 60 - 70 % (related to the total protein 
amount) or loading capacities of up to 50 % (related to the total excipient amount) were 
achieved. Moreover, NPs consisting of chitosan and sodium deoxycholate were 
characterised for comparison. As a result, the latter particle forming approach was not 
pursued further because the NPs consisting of chitosan and carboxymethylcellulose 
were regarded as more promising. 
Furthermore, a dosage form for the nasal application of the NPs was developed. For 
that purpose, they were spray dried with mannitol to get embedded in microparticles. 
This way the NPs were stabilised. Using an ultrasonic nozzle in combination with a high 
mannitol concentration of 20 %, particles in a suitable size range for nasal deposition of 
approximately 20 µm could be generated. Experiments with a nasal cast model showed 
the suitability of the formulation for nasal application. 
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The NPs could be redispersed from the microparticles almost in their original size. First 
in vitro uptake experiments in dendritic cells showed a concentration- and size-
dependent uptake. Smaller particles up to 500 nm were internalised in cells while larger 
particles (1 000 nm) stuck to the surface of the cells. Follow-up experiments will examine 
potential uptake mechanisms and subsequent activation of the dendritic cells. 
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7 Summary (German) 
Die Forschung zu mukosaler Impfung hat Nanopartikel (NP) als vielversprechenden 
Antigenträger mit adjuvanten Eigenschaften identifiziert. Häufig wird dabei Chitosan als 
Material zur Herstellung der NP verwendet. Um solche NP als trockenes Pulver 
applizierbar zu machen, können sie in eine mikropartikuläre Matrix (Nano-in-
Mikropartikel) inkorporiert werden. Die Mikropartikel sollen über die Nase appliziert 
werden und daher eine Partikelgröße von über 10 µm aufweisen, um eine nasale 
Deposition sicherzustellen. Nach erfolgter Deposition soll die mikropartikuläre Matrix 
die NP in ihrer ursprünglichen Größe freigeben. Für die Aufnahme der NP in 
immunkompetente, insbesondere in dendritische, Zellen eignet sich eine Größe von 
100 - 500 nm, wie aus der Literatur bekannt ist. 
Der Fokus dieser Arbeit lag insbesondere auf der Herstellung und Charakterisierung der 
NP. Diese wurden aus Chitosan und Carboxymethylcellulose hergestellt. Als 
Modellantigen wurde Ovalbumin verwendet. Die Partikelbildung zwischen den beiden 
Polymeren beruht auf einer Quervernetzung durch ionische Gelierung 
(Ladungsausgleich zwischen positiv geladenem Chitosan und negativ geladener 
Carboxymethylcellulose). Es wurden Einflüsse auf die Partikelstabilität, resultierende 
Partikelgröße und die Proteinverkapselung untersucht. NP im geeigneten 
Größenbereich von 100 - 500 nm konnten hergestellt werden. Das Modellantigen 
konnte mit den Nanopartikeln assoziiert werden. Abhängig von der verwendeten 
Methode konnte eine hohe Verkapselungseffizienz von bis zu 60 - 70 % (bezogen auf 
den gesamten Proteingehalt) oder eine hohe Partikelbeladung von bis zu 50 % 
(bezogen auf die gesamte Menge Partikelausgangsstoffe) erreicht werden. Darüber 
hinaus wurden auch NP bestehend aus Chitosan und Natriumdeoxycholat vergleichend 
charakterisiert. Daraus ergab sich, dass dieser Partikelformulierungsansatz nicht 
weiterverfolgt wurde, da die Partikel aus Chitosan und Carboxymethycellulose als 
vielversprechender angesehen werden. 
Im Weiteren wurde eine Darreichungsform für die nasale Gabe der NP entwickelt. Dafür 
wurden sie mittels Sprühtrocknung mit Mannitol in Mikropartikel eingebettet und 
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dadurch stabilisiert. Durch die Verwendung einer Ultraschalldüse und einer hohen 
Mannitol-Konzentration von 20 % konnten Partikel in einem geeigneten Größenbereich 
von ca. 20 µm generiert werden. Durch Versuche mit einem Nasenmodell konnte 
gezeigt werden, dass die entwickelte Formulierung prinzipiell geeignet für eine nasale 
Deposition ist. 
Die NP sind nach Auflösen der Mikropartikel annähernd in ihrer ursprünglichen Größe 
rekonstituiert worden. Es wurden erste in vitro Versuche zur Aufnahme in dendritischen 
Zellen durchgeführt. Diese zeigten, dass die Partikel konzentrations- und 
größenabhängig aufgenommen werden. Kleinere Partikel (bis 500 nm) wurden in die 
Zellen aufgenommen, während größere (1 000 nm) eher außen an den Zellen 
anhefteten. Weiterführende Untersuchungen werden sich mit möglichen 
Aufnahmemechanismen und der anschließenden Aktivierung der dendritischen Zellen 
beschäftigen. 
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9 Appendix 
9.1 Abbreviations 
APC Antigen presenting cells 
BCA Bicinchoninic acid 
BF Brightfield 
CD Cluster of differentiation 
CMC Sodium carboxymethylcellulose 
DC Dendritic cell 
DDA Degree of deacetylation 
DLS Dynamic light scattering 
DOC Sodium deoxycholate 
DoE Design of Experiments 
DVS Dynamic vapour sorption 
FITC Fluorescein isothiocyanate isomer I 
FPF Fine particle fraction 
HAc Acetic acid 
hDC Human dendritic cells 
HPMC Hydroxypropyl methylcellulose 
IEP Isoelectric point 
Ig Immunoglobulin 
INS Internalisation score 
ITC Isothermal titration calorimetry 
LC Loading capacity 
LE Loading efficiency 
MALS Multiple angle light scattering 
M-cells Microfold cells 
MFI Median fluorescence intensity 
MHC Major histocompatibility complex 
MOC Micro-orifice collector 
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NALT Nose-associated lymphoid tissue 
NGI Next Generation Impactor 
NiM Nano-in-Microparticle 
NMR Nuclear magnetic resonance spectroscopy 
NP Nanoparticle 
OVA Ovalbumin 
PBS Phosphate buffered saline 
PDI Polydispersity index 
PEG Polyethylene glycol 
Ph. Eur. European Pharmacopoeia 
PVA Polyvinyl alcohol 
Q3 Cumulant frequency of a volume-based distribution 
q3* Probability density function of a volume-based distribution 
RSD Relative standard deviation 
SD Standard deviation 
SEC Size exclusion chromatography 
SEM Scanning electron microscopy 
sIg Secretory immunoglobulin 
TH Helper T-cell 
TPP Penta-sodium triphosphate 
TSP Deuterated sodium trimethylsilyl propionate 
UDS Unit dose system 
UK United Kingdom 
USA United States of America 
WHO World Health Organisation 
ZP Zeta potential 
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9.2 Units 
% Per cent, 10-2 
° Degree(s) 
°C Degree(s) Celsius 
µ Micro (if followed by another unit), 10-6
bar Bar, 105 N 
c* Centi (if followed by another unit), 10-2
d Day(s) 
Da Dalton, corresponds to g mol-1
g Gram(s) 
Hz Hertz, s-1 
k* Kilo (if followed by another unit), 103
L Litre(s) 
M Molar, mol L-1 
m Metre(s) 
m* Milli (if followed by another unit), 10-3
M* Mega (if followed by another unit), 106
min Minute(s) 
N Newton 
n* Nano (if followed by another unit), 10-9
Pa Pascal, N m-2 
pH Potential of hydrogen 
ppm Part(s) per million 
rcf Relative centrifugal field 
rpm Rounds per minute, min-1
s Second(s) 
S Siemens 
wt% Mass fraction, 10-2 
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9.3 Buffers 
10x PBS, pH 7.4 
NaCl 
KH2PO4 
Na2HPO4 
KCl 
Ultrapure water 
80 g
2 g
11.5 g
2 g
ad 1.0 L
 
PBS, pH 7.4 
10x PBS 
Ultrapure water 
100 mL
ad 1.0 L
 
Modified 10x PBS 
NaCl 
10x PBS 
100 g
ad 1.0 L
 
Acetate buffer, pH 3.7 
0.2 M NaAc 
0.2 M HAc 
10 mL
90 mL
 
Acetate buffer, pH 4 
0.2 M NaAc 
0.2 M HAc 
18 mL
82 mL
 
Acetate buffer, pH 4.5 
0.2 M NaAc 
0.2 M HAc 
43 mL
57 mL
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